carmustine has been researched along with Local Neoplasm Recurrence in 213 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage." | 9.22 | The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016) |
| "The purpose of this study was to evaluate the activity, measured in terms of progression-free survival (PFS) and response rates, of 1,3-bis(chloro-ethyl)-1-nitrosourea (BCNU) plus temozolomide in adult patients with recurrent glioblastoma multiforme." | 9.11 | Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. ( Chang, SM; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schold, SC; Yung, WK, 2004) |
| "Irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma." | 9.11 | Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. ( Affronti, ML; Allen, D; Bigner, DD; Bohlin, C; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Lentz, C; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Schweitzer, H; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K, 2004) |
| "This New Approaches to Brain Tumor Therapy CNS Consortium study sought to determine the maximum-tolerated dose (MTD) of carmustine (BCNU) that can be implanted in biodegradable polymers following resection of recurrent high-grade gliomas and the systemic BCNU exposure with increasing doses of interstitial BCNU." | 9.10 | Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. ( Barker, F; Bruce, J; Fisher, J; Grossman, SA; Hilt, D; Judy, K; Olivi, A; Olsen, J; Piantadosi, S; Tatter, S, 2003) |
| "Twenty six (17 males) patients with glioblastoma (GBL), median age 55 years, median Karnofsky Index (KI) 70/100, and 11 patients (9 males) with anaplastic astrocytoma (AA), median age 56 years, median KI 70/100 were treated at recurrence with dibromodulcitol (DBD) 1400 mg/m2 on day 1, BCNU 150 mg/m2 on day 2, and procarbazine (PCZ) 150 mg/day on days 1 to 15." | 9.08 | Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study. ( De Witte, O; Hildebrand, J; Sahmoud, T, 1998) |
| "There is a growing body of evidence that carmustine wafer implantation during surgery is an effective therapeutic adjunct to the standard combined radio-chemotherapy regimen using temozolomide in newly diagnosed and recurrent high-grade glioma patient management with a statistically significant survival benefit demonstrated across several randomized clinical trials, as well as prospective and retrospective studies (grade A recommendation)." | 8.95 | Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery. ( Caire, F; Guyotat, J; Menei, P; Metellus, P; Pallud, J; Roux, A, 2017) |
| "Carmustine wafers (CW; Gliadel(®) wafers) are approved to treat newly-diagnosed high-grade glioma (HGG) and recurrent glioblastoma." | 8.91 | Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. ( Chowdhary, SA; Newton, HB; Ryken, T, 2015) |
| "Implantation of biodegradable Carmustine wafers in patients with malignant glioma is not generally recommended when the ventricular system is opened during tumor resection." | 8.02 | Implantation of Carmustine wafers after resection of malignant glioma with and without opening of the ventricular system. ( Abboud, T; Bettag, C; Bock, HC; Hussein, A; Mielke, D; Rohde, V; Sachkova, A, 2021) |
| "To retrospectively determine the safety and efficacy of combined chemotherapy with carmustine (BCNU) wafer, bevacizumab, and temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma (GBM)." | 7.88 | Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. ( Akiyama, Y; Enatsu, R; Kimura, Y; Mikami, T; Mikuni, N; Wanibuchi, M, 2018) |
| "In this retrospective study, we identified adult patients with histologically confirmed glioblastoma (WHO grade IV) who were treated with lomustine or carmustine in combination with bevacizumab as a second or third regimen after failing an alternative initial bevacizumab-containing regimen." | 7.80 | Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. ( Alexander, BM; Beroukhim, R; Doherty, L; Hempfling, K; Huang, RY; LaFrankie, D; Lee, EQ; Nayak, L; Norden, AD; Rahman, R; Rai, A; Reardon, DA; Rifenburg, J; Rinne, ML; Ruland, S; Wen, PY, 2014) |
| "Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival." | 7.74 | Fatal outcome related to carmustine implants in glioblastoma multiforme. ( Barcia, JA; Barcia-Mariño, C; Gallego, JM, 2007) |
| "One hundred forty-three patients with cutaneous T cell lymphoma were treated with topical carmustine (BCNU)." | 7.68 | Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. ( Crain, WR; Epstein, EH; Zackheim, HS, 1990) |
| "A prospective, nonrandomized trial was performed of the four-drug chemotherapy protocol consisting of dacarbazine, carmustine, cisplatin, and tamoxifen citrate given to high-risk patients for recurrence of melanoma after local regional treatment." | 7.68 | Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study. ( Cruse, CW; Klein, CJ; Reintgen, DS; Saba, HI; Wells, KE, 1992) |
| "33 patients with advanced refractory multiple myeloma received a combination of vincristine, cyclophosphamide, carmustine, melphalan and steroids (M-2 protocol)." | 7.67 | M-2 protocol for melphalan-resistant and relapsing multiple myeloma. ( Cavo, M; Galieni, P; Gobbi, M; Tassi, C; Tura, S, 1988) |
| "Irinotecan is a water-soluble derivative of camptothecin, an alkylator originally extracted from the Chinese tree Camptotheca acuminata." | 6.42 | The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. ( Friedman, HS; Houghton, PJ; Keir, ST, 2003) |
| "During follow-up, local disease progression was observed in 27 patients, and 23 of them died." | 5.35 | Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. ( Albright, RE; Breneman, JC; Darakchiev, BJ; Warnick, RE, 2008) |
| "Diaziquone (AZQ) is a lypophilic alkylating agent that crosses the blood-brain barrier and has shown broad activity in animal tumor models." | 5.27 | Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas. ( Bender, JF; Chaffee, B; Ensminger, WD; Gebarski, S; Greenberg, HS; Grillo-Lopez, AJ; Layton, PB; Meyer, M, 1986) |
| "Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage." | 5.22 | The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016) |
| "Carmustine (1,3-bis[2-chloroetyl]-1-nitrosurea (BCNU)) wafers are approved for the local treatment of newly diagnosed and recurrent malignant glioma." | 5.14 | The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series. ( Ciccarino, P; d'Avella, D; Del Moro, G; Della Puppa, A; Denaro, L; Manara, R; Paola Gardiman, M; Rossetto, M; Rotilio, A; Scienza, R, 2010) |
| "The purpose of this study was to evaluate the activity, measured in terms of progression-free survival (PFS) and response rates, of 1,3-bis(chloro-ethyl)-1-nitrosourea (BCNU) plus temozolomide in adult patients with recurrent glioblastoma multiforme." | 5.11 | Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. ( Chang, SM; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schold, SC; Yung, WK, 2004) |
| "Irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma." | 5.11 | Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. ( Affronti, ML; Allen, D; Bigner, DD; Bohlin, C; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Lentz, C; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Schweitzer, H; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K, 2004) |
| "This New Approaches to Brain Tumor Therapy CNS Consortium study sought to determine the maximum-tolerated dose (MTD) of carmustine (BCNU) that can be implanted in biodegradable polymers following resection of recurrent high-grade gliomas and the systemic BCNU exposure with increasing doses of interstitial BCNU." | 5.10 | Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. ( Barker, F; Bruce, J; Fisher, J; Grossman, SA; Hilt, D; Judy, K; Olivi, A; Olsen, J; Piantadosi, S; Tatter, S, 2003) |
| " We conducted a randomised, placebo-controlled, prospective study to evaluate the effectiveness of biodegradable polymers impregnated with carmustine to treat recurrent malignant gliomas." | 5.08 | Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. ( Black, K; Brem, H; Brem, S; Burger, PC; Mohr, G; Piantadosi, S; Selker, R; Sisti, M; Vick, NA; Walker, M, 1995) |
| "Twenty six (17 males) patients with glioblastoma (GBL), median age 55 years, median Karnofsky Index (KI) 70/100, and 11 patients (9 males) with anaplastic astrocytoma (AA), median age 56 years, median KI 70/100 were treated at recurrence with dibromodulcitol (DBD) 1400 mg/m2 on day 1, BCNU 150 mg/m2 on day 2, and procarbazine (PCZ) 150 mg/day on days 1 to 15." | 5.08 | Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study. ( De Witte, O; Hildebrand, J; Sahmoud, T, 1998) |
| " Conventional phase II clinical trials conducted in patients with recurrent or progressive brainstem gliomas using single chemotherapy agents such as cyclophosphamide, carboplatin, cisplatin, etoposide and thiotepa or combinations of chemotherapy agents have produced low response rates in the range of 15-20%." | 5.08 | Contemporary chemotherapy issues for children with brainstem gliomas. ( Allen, JC; Siffert, J, 1996) |
| "Twenty-six children with advanced neuroblastoma were consolidated with cisplatin, BCNU, etoposide, melphalan, 21 Gy of local radiotherapy, and bone marrow rescue in a multicenter study." | 5.07 | High-dose consolidation with local radiation and bone marrow rescue in patients with advanced neuroblastoma. ( Bender-Götze, C; Burdach, S; Ebell, W; Friedrich, W; Herrmann, F; Klingebiel, T; Koscielniak, E; Kremens, B; Schmid, H; Siegert, W, 1994) |
| "A multi-institutional cooperative study of patients with locally advanced, recurrent, or metastatic gastric adenocarcinoma who had not previously received chemotherapy was conducted, prospectively randomizing patients to receive either doxorubicin or the three-drug combination, 5-fluorouracil (5-FU), doxorubicin (Adriamycin; Adria Laboratories, Columbus, Ohio), and BCNU (FAB)." | 5.06 | Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. ( Fox, RM; Gill, G; Levi, JA; Tattersall, MH; Thomson, D; Woods, RL, 1986) |
| "A number of cooperative-group and single-institution studies have shown that BCNU used in combination with prednisone alone or with melphalan,cyclophosphamide, and prednisone is useful for remission induction in patients with previously untreated multiple myeloma." | 5.04 | Nitrosoureas in multiple myeloma. ( Salmon, SE, 1976) |
| "There is a growing body of evidence that carmustine wafer implantation during surgery is an effective therapeutic adjunct to the standard combined radio-chemotherapy regimen using temozolomide in newly diagnosed and recurrent high-grade glioma patient management with a statistically significant survival benefit demonstrated across several randomized clinical trials, as well as prospective and retrospective studies (grade A recommendation)." | 4.95 | Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery. ( Caire, F; Guyotat, J; Menei, P; Metellus, P; Pallud, J; Roux, A, 2017) |
| "Carmustine wafers (CW; Gliadel(®) wafers) are approved to treat newly-diagnosed high-grade glioma (HGG) and recurrent glioblastoma." | 4.91 | Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. ( Chowdhary, SA; Newton, HB; Ryken, T, 2015) |
| "Implantation of biodegradable Carmustine wafers in patients with malignant glioma is not generally recommended when the ventricular system is opened during tumor resection." | 4.02 | Implantation of Carmustine wafers after resection of malignant glioma with and without opening of the ventricular system. ( Abboud, T; Bettag, C; Bock, HC; Hussein, A; Mielke, D; Rohde, V; Sachkova, A, 2021) |
| "To retrospectively determine the safety and efficacy of combined chemotherapy with carmustine (BCNU) wafer, bevacizumab, and temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma (GBM)." | 3.88 | Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. ( Akiyama, Y; Enatsu, R; Kimura, Y; Mikami, T; Mikuni, N; Wanibuchi, M, 2018) |
| "Patients with glioblastoma treated with BCNU wafer implantation for recurrence frequently receive frontline chemoradiotherapy with temozolomide as part of the Stupp protocol." | 3.80 | Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma. ( Ewelt, C; Hänggi, D; Isik, G; Sabel, M; Samis Zella, MA; Schroeteler, J; Slotty, PJ; Steiger, HJ; Wallocha, M, 2014) |
| "In this retrospective study, we identified adult patients with histologically confirmed glioblastoma (WHO grade IV) who were treated with lomustine or carmustine in combination with bevacizumab as a second or third regimen after failing an alternative initial bevacizumab-containing regimen." | 3.80 | Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. ( Alexander, BM; Beroukhim, R; Doherty, L; Hempfling, K; Huang, RY; LaFrankie, D; Lee, EQ; Nayak, L; Norden, AD; Rahman, R; Rai, A; Reardon, DA; Rifenburg, J; Rinne, ML; Ruland, S; Wen, PY, 2014) |
| "Carmustine (BCNU: N,N'-bis[2-chloroethyl]-N-nitrosourea) wafers are a local chemotherapeutic agent for the treatment of malignant glioma." | 3.76 | Incorporating BCNU wafers into malignant glioma treatment: European case studies. ( Balossier, A; Dörner, L; Emery, E; Heese, O; Mehdorn, HM; Menei, P; Singh, J, 2010) |
| "Glioblastoma patients have a poor prognosis, even after surgery, radiotherapy, and chemotherapy with temozolomide or 1,3-bis(2-chloroethy)-1-nitrosourea." | 3.76 | Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres. ( Cochran, BH; Daou, MC; Gilbert, CA; Li, L; Mihaliak, AM; Moser, RP; Reeves, A; Ross, AH, 2010) |
| "Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival." | 3.74 | Fatal outcome related to carmustine implants in glioblastoma multiforme. ( Barcia, JA; Barcia-Mariño, C; Gallego, JM, 2007) |
| "Twenty-seven children and adolescents with malignant astrocytomas [17 glioblastoma multiforme and 10 anaplastic astrocytoma (AA)] following initial tumor progression, received myeloablative chemotherapy followed by autologous marrow rescue with one of three thiotepa and etoposide-based chemotherapy regimens, administered alone (n = 11) or combined with carmustine (n = 5) or carboplatin (n = 11)." | 3.74 | Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group. ( Boyett, JM; Dhall, G; Dunkel, IJ; Finlay, JL; Gardner, SL; Goldman, S; Packer, RJ; Pollack, IF; Rosenblum, MK; Stanley, P; Wallace, D; Yates, AJ; Zimmerman, RA, 2008) |
| " The typically local recurrence of glioblastoma in about 80% of the cases has prompted intracavitary treatments of which presently only a biodegradable wafer containing carmustine has shown statistically significant benefit regarding survival in three phase III trials." | 3.72 | Intracavitary chemotherapy for glioblastoma: present status and future directions. ( Hilt, D; Lamszus, K; Westphal, M, 2003) |
| "We treated 54 patients, newly diagnosed for glioblastoma, with systemic chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks) and radiotherapy soon after surgery." | 3.70 | Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. ( Boiardi, A; Broggi, G; Eoli, M; Pozzi, A; Salmaggi, A; Silvani, A, 1999) |
| "Eighteen patients had carmustine (BCNU) wafers implanted during reoperation for malignant glioma; three patients had empty, placebo wafers placed." | 3.70 | Serial CT and MR imaging of carmustine wafers. ( Chiowanich, P; Cozzens, JW; Gorey, MT; Grenier, Y; Meyer, JR; Prager, JM, 2000) |
| "A retrospective study of 30 cases of Hodgkin disease in patients who underwent high-dose carmustine, etoposide, and cyclophosphamide chemotherapy with PBSC support was performed." | 3.70 | Hematologic toxic reaction to radiation therapy adjuvant to autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin disease. ( Bogart, JA; Chung, CT; Ryu, S; Ungureanu, C; Zamkoff, KW, 2000) |
| "A prospective, nonrandomized trial was performed of the four-drug chemotherapy protocol consisting of dacarbazine, carmustine, cisplatin, and tamoxifen citrate given to high-risk patients for recurrence of melanoma after local regional treatment." | 3.68 | Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study. ( Cruse, CW; Klein, CJ; Reintgen, DS; Saba, HI; Wells, KE, 1992) |
| "One hundred forty-three patients with cutaneous T cell lymphoma were treated with topical carmustine (BCNU)." | 3.68 | Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. ( Crain, WR; Epstein, EH; Zackheim, HS, 1990) |
| "33 patients with advanced refractory multiple myeloma received a combination of vincristine, cyclophosphamide, carmustine, melphalan and steroids (M-2 protocol)." | 3.67 | M-2 protocol for melphalan-resistant and relapsing multiple myeloma. ( Cavo, M; Galieni, P; Gobbi, M; Tassi, C; Tura, S, 1988) |
| "The high-dose BCNU-loaded PLGA implants were safe for Chinese patients with recurrent malignant gliomas and further investigation for efficacy is warranted." | 2.79 | Safety evaluation of high-dose BCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas. ( Chen, YS; Chen, ZH; Chen, ZP; Gao, WC; Guo, CC; Ke, C; Li, X; Lin, FH; Lv, YC; Mou, YG; Sai, K; Wang, J; Yang, QY; Zeng, J; Zhang, XH; Zhong, MG, 2014) |
| "Patients with brain metastases had improvements in their cognitive trajectory, especially memory and executive function, after treatment with resection plus CW." | 2.78 | Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers. ( Booth-Jones, M; Brem, S; Ewend, MG; Jain, S; Meyers, CA; Palmer, G, 2013) |
| "Dose-escalated (90)Y ibritumomab tiuxetan may be safely combined with high-dose BEAM with autologous transplantation and has the potential to be more effective than standard-dose radioimmunotherapy." | 2.74 | Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. ( Erwin, W; Evens, AM; Gordon, LI; Inwards, DJ; Mehta, J; Micallef, I; Molina, A; Patton, D; Rademaker, AW; Singhal, S; Spies, S; Tallman, MS; Weitner, BB; White, CA; Williams, SF; Winter, JN; Wiseman, G; Zimmer, M, 2009) |
| " Two patients had severe adverse events thought to be related to wafer placement, one with seizures alone, and one with seizures and subsequent respiratory compromise." | 2.73 | Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. ( Brem, S; Carey, LA; Cush, S; Ewend, MG; Gilbert, M; Goodkin, R; Penar, PL; Varia, M, 2007) |
| "Twenty-three patients were treated (22 with glioblastoma multiforme and one with anaplastic astrocytoma)." | 2.69 | Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. ( Ashley, DM; Bigner, DD; Cokgor, I; Colvin, OM; Dolan, ME; Ewesuedo, RB; Friedman, AH; Friedman, HS; Garcia-Turner, AM; Haglund, MM; Herndon, JE; Long, L; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, J; Stewart, ES; Tourt-Uhlig, S, 2000) |
| "Twenty patients with recurrent brain tumors aged 0." | 2.69 | Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. ( Boyett, JM; Dunkel, IJ; Finlay, JL; Gardner, S; Garvin, JH; Goldman, S; Gollamudi, S; Guruangan, S; Merchant, TE; Rosenblum, M, 1998) |
| "Seventy-nine patients harboring recurrent brain tumors received four cycles of infraophthalmic carotid injections of 160 mg of carmustine." | 2.67 | Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors. ( Hager, B; Hannisdal, E; Hirschberg, H; Nome, O; Watne, K, 1992) |
| "Malignant gliomas have been difficult to treat with chemotherapy." | 2.67 | Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. ( Black, KL; Brem, H; Burger, PC; Ciric, IS; Cozzens, JW; Eller, TW; Friedman, AH; Mahaley, MS; Schold, SC; Vick, NA, 1991) |
| "Glioblastoma is the most common adult malignant primary brain tumor." | 2.52 | Current medical treatment of glioblastoma. ( Ahluwalia, MS; Peereboom, DM; Venur, VA, 2015) |
| "Malignant gliomas are very difficult neoplasms for clinicians to treat." | 2.44 | Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience. ( Bohan, E; Brem, H; Hussain, N; Kleinberg, L; Lawson, HC; Olivi, A; Park, MC; Sampath, P; Weingart, J, 2007) |
| "High-grade glioma is a devastating disease that leaves the majority of its victims dead within 2 years." | 2.44 | Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. ( Kleinberg, LR; Lin, SH, 2008) |
| "Esthesioneuroblastoma is an uncommon malignancy of the nasal vault with a treatment regimen consisting of surgical resection followed by radiotherapy for primary lesions and addition of chemotherapy for patients with advanced, recurrent or metastatic lesions." | 2.43 | Intracavitary chemotherapy (Gliadel) for recurrent esthesioneuroblastoma: case report and review of the literature. ( Donahue, JE; Park, MC; Sampath, P; Weaver, CE, 2006) |
| "Irinotecan is a water-soluble derivative of camptothecin, an alkylator originally extracted from the Chinese tree Camptotheca acuminata." | 2.42 | The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. ( Friedman, HS; Houghton, PJ; Keir, ST, 2003) |
| "New approaches to malignant glioma are being actively investigated." | 2.42 | Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. ( Brem, H; Guerin, C; Lawson, HC; Olivi, A; Weingart, JD, 2004) |
| "High-grade malignant gliomas are inevitably fatal, despite every effort to improve this prognosis, including various radiotherapeutic modalities, radio- and chemotherapeutic associations, and combinations of several drugs." | 2.41 | High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults. ( Basso, U; Brandes, AA; Monfardini, S; Palmisano, V; Pasetto, LM, 2001) |
| " Carmustine (BCNU) has been shown to have limited activity at conventional dosage but is still the standard chemotherapy." | 2.41 | [Role of high-dose chemotherapy with hemopoietic stem-cell support in the treatment of adult patients with high-grade glioma]. ( Alcaraz, L; Benboubker, L; Bergemer-Fouquet, AM; Calais, G; Colombat, P; Destrieux, C; Jan, M; Linassier, C, 2001) |
| "BCNU wafer implantation after resection of recurrent GBM is a reasonably safe treatment in patients aged >65 years." | 1.46 | Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma. ( Daubner, D; Juratli, TA; Klein, J; Krex, D; Radev, Y; Schackert, G; Soucek, S, 2017) |
| " Additionally, medical records of 163 patients treated with BCNU for recurrent glioma WHO grade II to IV were retrospectively evaluated for BCNU-related side effects classified according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 2." | 1.43 | Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients. ( Ahmadi, R; Bermejo, JL; Capper, D; Chatziaslanidou, D; Exner, J; Herold-Mende, C; Jungk, C; Unterberg, A; von Deimling, A, 2016) |
| "Combining Gliadel wafers and radiochemotherapy with TMZ may carry the risk of increased adverse events (AE)." | 1.38 | Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. ( Anile, C; Balducci, M; Chiesa, S; De Bonis, P; Fiorentino, A; Maira, G; Mangiola, A; Pompucci, A, 2012) |
| "Forty-two patients died as a result of disease progression, and nine died as a result of regimen-related toxicity." | 1.35 | High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. ( Caballero, D; Canals, C; Finke, J; Goldstone, A; Hunter, A; Kienast, J; Kobbe, G; Kolb, HJ; Kyriakou, C; Metzner, B; Oberg, G; Reimer, P; Schmitz, N; Sureda, A; Theorin, N, 2008) |
| "During follow-up, local disease progression was observed in 27 patients, and 23 of them died." | 1.35 | Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. ( Albright, RE; Breneman, JC; Darakchiev, BJ; Warnick, RE, 2008) |
| "Cure rates of Hodgkin's disease (HD) with chemotherapy and/or radiotherapy are high." | 1.34 | [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab]. ( Al-Ali, HK; Niederwieser, D; Wittekind, C, 2007) |
| "With respect to the cerebral edema that can be associated with the carmustine implants, there can appear images in follow-up that are suggestive of relapse." | 1.33 | Patient with resected anaplastic astrocytoma and an image suggestive of relapse. ( Carrato Mena, A; Guillén Ponce, C; Maciá Escalante, S; Rodríguez Lescure, A; Sáez Castán, J; Segura Ibáñez, JM, 2006) |
| " Despite prompt initiation of antimycotic therapy the outcome was fatal; dosage of conventional and liposomal amphotericin B was limited due to treatment-related toxicities." | 1.31 | A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation. ( Bethe, U; Cornely, OA; Pels, H; Ritzkowsky, A; Seibold, M; Soehngen, D; Toepelt, K, 2001) |
| "Despite the fact that follicular lymphomas are both chemo- and radiosensitive, the disease is generally non-curable." | 1.31 | Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. ( Berglund, A; Carlson, K; Enblad, G; Glimelius, B; Hagberg, H, 2000) |
| "The hypodense, roughly spherical cysts clearly demonstrated clinically significant mass effect, and required reoperation despite treatment with high-dose corticosteroids." | 1.31 | Tumor bed cyst formation after BCNU wafer implantation: report of two cases. ( Engelhard, HH, 2000) |
| "Fifty-one consecutive patients with Hodgkin's disease (HD) have been treated with high-dose chemotherapy (HDT) and transplantation of autologous bone marrow (BM) (n = 44), autologous BM plus peripheral blood stem cells (PBSC) (n = 2), PBSC (n = 1), syngeneic (n = 1), or allogeneic BM (n = 3)." | 1.29 | High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease. ( Dreger, P; Gassmann, W; Glass, B; Haferlach, T; Horst, HA; Löffler, H; Ollech-Chwoyka, J; Schmitz, N; Suttorp, M, 1993) |
| "Sixty-one patients with relapsed Hodgkin's disease who had failed a mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)- and a doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)-like regimen were treated with a high-dose combination chemotherapy containing cyclophosphamide, carmustine, and etoposide (CBV) and autologous bone marrow transplantation (ABMT)." | 1.28 | Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. ( Armitage, JO; Dicke, KA; Hagemeister, FB; Horwitz, LJ; Jagannath, S; Kessinger, A; Smith, K; Tucker, SL; Vaughan, WP; Velasquez, WS, 1989) |
| "She developed progressive, pulmonary fibrosis as a consequence of chemotherapy, which lead to her death." | 1.27 | Chemotherapy-induced fatal pulmonary fibrosis. ( Révész, T; Somló, P, 1984) |
| "Thirty-one patients with metastatic brain tumors that either failed to respond or recurred after conventional therapy were treated by intra-arterial infusion of 100 mg/m2 of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) into either a carotid or vertebral artery." | 1.27 | Intra-arterial BCNU in the treatment of metastatic brain tumors. ( Byrne, TN; Cascino, TL; Deck, MD; Posner, JB, 1983) |
| "Diaziquone (AZQ) is a lypophilic alkylating agent that crosses the blood-brain barrier and has shown broad activity in animal tumor models." | 1.27 | Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas. ( Bender, JF; Chaffee, B; Ensminger, WD; Gebarski, S; Greenberg, HS; Grillo-Lopez, AJ; Layton, PB; Meyer, M, 1986) |
| "Positive results were obtained in the treatment of oligodendrogliomas and astrocytomas grade III and IV." | 1.27 | Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations. ( Jaksche, H; Loew, F; Papavero, L, 1987) |
| "Six children with grade II astrocytomas were treated with combination chemotherapy consisting of 1,3 bis(2-chloroethyl) 1-nitrosourea (BCNU)." | 1.26 | Chemotherapy in recurrent noncystic low-grade astrocytomas of the cerebrum in children. ( Bremer, AM; Cohen, M; Freeman, AI; Sinks, LF; Sumer, T; Thomas, PR, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 49 (23.00) | 18.7374 |
| 1990's | 38 (17.84) | 18.2507 |
| 2000's | 61 (28.64) | 29.6817 |
| 2010's | 53 (24.88) | 24.3611 |
| 2020's | 12 (5.63) | 2.80 |
| Authors | Studies |
|---|---|
| Sapelli, J | 1 |
| Filho, JS | 1 |
| Matias Vieira, GM | 1 |
| Moura, FL | 1 |
| Germano, JN | 1 |
| de Lima, VCC | 1 |
| Reiss, SN | 1 |
| Yerram, P | 1 |
| Modelevsky, L | 1 |
| Grommes, C | 1 |
| Friend, BD | 1 |
| Muhsen, IN | 1 |
| Patel, S | 1 |
| Hill, LC | 1 |
| Lulla, P | 1 |
| Ramos, CA | 1 |
| Pingali, SR | 1 |
| Kamble, RT | 1 |
| John, TD | 1 |
| Salem, B | 1 |
| Bhar, S | 1 |
| Doherty, EE | 1 |
| Craddock, J | 1 |
| Sasa, G | 1 |
| Wu, M | 1 |
| Wang, T | 1 |
| Martinez, C | 1 |
| Krance, RA | 1 |
| Heslop, HE | 1 |
| Carrum, G | 1 |
| Schenone, L | 1 |
| Houillier, C | 1 |
| Tanguy, ML | 1 |
| Choquet, S | 1 |
| Agbetiafa, K | 1 |
| Ghesquières, H | 1 |
| Damaj, G | 1 |
| Schmitt, A | 1 |
| Bouabdallah, K | 1 |
| Ahle, G | 1 |
| Gressin, R | 1 |
| Cornillon, J | 1 |
| Houot, R | 1 |
| Marolleau, JP | 2 |
| Fornecker, LM | 1 |
| Chinot, O | 2 |
| Peyrade, F | 1 |
| Bouabdallah, R | 2 |
| Moluçon-Chabrot, C | 1 |
| Gyan, E | 1 |
| Chauchet, A | 1 |
| Casasnovas, O | 1 |
| Oberic, L | 1 |
| Delwail, V | 1 |
| Abraham, J | 1 |
| Roland, V | 1 |
| Waultier-Rascalou, A | 1 |
| Willems, L | 1 |
| Morschhauser, F | 1 |
| Fabbro, M | 1 |
| Ursu, R | 1 |
| Thieblemont, C | 1 |
| Jardin, F | 1 |
| Tempescul, A | 1 |
| Malaise, D | 1 |
| Touitou, V | 1 |
| Nichelli, L | 1 |
| Le Garff-Tavernier, M | 1 |
| Plessier, A | 1 |
| Bourget, P | 1 |
| Bonmati, C | 1 |
| Wantz-Mézières, S | 1 |
| Giordan, Q | 1 |
| Dorvaux, V | 1 |
| Charron, C | 1 |
| Jabeur, W | 1 |
| Hoang-Xuan, K | 1 |
| Taillandier, L | 1 |
| Soussain, C | 1 |
| Chen, S | 1 |
| Qiu, Q | 1 |
| Wang, D | 1 |
| She, D | 1 |
| Yin, B | 1 |
| Gu, G | 1 |
| Chai, M | 1 |
| Heo, DN | 1 |
| He, H | 1 |
| Wang, J | 2 |
| Ahern, K | 1 |
| Pham, J | 1 |
| Sanderson, R | 1 |
| Correia De Farias, M | 1 |
| Walsh, K | 1 |
| Arshad, S | 1 |
| Fang, X | 1 |
| Ahn, KW | 1 |
| Kaur, M | 1 |
| Scordo, M | 1 |
| Sauter, CS | 1 |
| Furqan, F | 1 |
| Awan, FT | 1 |
| Hamadani, M | 1 |
| Ron-Magaña, AL | 1 |
| Fernandez-Vargas, OE | 1 |
| Barrera-Chairez, E | 1 |
| Ron-Guerrero, CS | 1 |
| Bañuelos-Ávila, AJ | 1 |
| Mouhieddine, TH | 1 |
| Barlogie, B | 1 |
| Teruya-Feldstein, J | 1 |
| Erthal, LCS | 1 |
| Gobbo, OL | 1 |
| Ruiz-Hernandez, E | 1 |
| Shibahara, I | 2 |
| Miyasaka, K | 1 |
| Sekiguchi, A | 1 |
| Ishiyama, H | 1 |
| Inukai, M | 2 |
| Yasui, Y | 2 |
| Watanabe, T | 2 |
| Sato, S | 2 |
| Hide, T | 1 |
| Kumabe, T | 3 |
| Bettag, C | 1 |
| Hussein, A | 1 |
| Sachkova, A | 1 |
| Bock, HC | 2 |
| Mielke, D | 1 |
| Rohde, V | 1 |
| Abboud, T | 1 |
| Kürzel, S | 1 |
| Blaudszun, AR | 1 |
| Stahl, L | 1 |
| Herbst, R | 1 |
| Kroschinsky, F | 1 |
| Birkmann, J | 1 |
| Hänel, A | 1 |
| Schaefer-Eckart, K | 1 |
| Ehninger, G | 1 |
| Fiedler, F | 1 |
| Bornhäuser, M | 1 |
| Fricke, S | 1 |
| Hänel, M | 1 |
| Klein, J | 1 |
| Juratli, TA | 1 |
| Radev, Y | 1 |
| Daubner, D | 1 |
| Soucek, S | 1 |
| Schackert, G | 1 |
| Krex, D | 1 |
| Ham, SW | 1 |
| Jeon, HY | 1 |
| Kim, H | 1 |
| Roux, A | 1 |
| Caire, F | 1 |
| Guyotat, J | 1 |
| Menei, P | 2 |
| Metellus, P | 2 |
| Pallud, J | 1 |
| Saleh, K | 1 |
| Danu, A | 1 |
| Koscielny, S | 1 |
| Legoupil, C | 1 |
| Pilorge, S | 1 |
| Castilla-Llorente, C | 1 |
| Ghez, D | 1 |
| Lazarovici, J | 1 |
| Michot, JM | 1 |
| Khalife-Saleh, N | 1 |
| Lapierre, V | 1 |
| Alenxandrova, K | 1 |
| Arfi-Rouche, J | 1 |
| Bourhis, JH | 1 |
| Ribrag, V | 1 |
| Hanihara, M | 1 |
| Dan, M | 1 |
| Kuroda, H | 1 |
| Inamura, A | 1 |
| Hara, A | 1 |
| Akiyama, Y | 1 |
| Kimura, Y | 1 |
| Enatsu, R | 1 |
| Mikami, T | 1 |
| Wanibuchi, M | 1 |
| Mikuni, N | 1 |
| Asano, K | 1 |
| Kurose, A | 1 |
| Kamataki, A | 1 |
| Kato, N | 1 |
| Ogawa, K | 1 |
| Katayama, K | 1 |
| Kakuta, K | 1 |
| Fumoto, T | 1 |
| Ohkuma, H | 1 |
| Cardona, AF | 1 |
| Rojas, L | 1 |
| Wills, B | 1 |
| Ruiz-Patiño, A | 1 |
| Abril, L | 1 |
| Hakim, F | 1 |
| Jiménez, E | 1 |
| Useche, N | 1 |
| Bermúdez, S | 1 |
| Mejía, JA | 1 |
| Ramón, JF | 1 |
| Carranza, H | 1 |
| Vargas, C | 2 |
| Otero, J | 1 |
| Archila, P | 1 |
| Rodríguez, J | 2 |
| Behaine, J | 1 |
| González, D | 1 |
| Jacobo, J | 1 |
| Cifuentes, H | 1 |
| Feo, O | 1 |
| Penagos, P | 1 |
| Pineda, D | 1 |
| Ricaurte, L | 1 |
| Pino, LE | 1 |
| Marquez, JC | 1 |
| Mantilla, MI | 1 |
| Ortiz, LD | 1 |
| Balaña, C | 1 |
| Rosell, R | 1 |
| Zatarain-Barrón, ZL | 1 |
| Arrieta, O | 1 |
| Ng, ZY | 1 |
| Bishton, M | 1 |
| Ritchie, D | 1 |
| Campbell, R | 1 |
| Gilbertson, M | 1 |
| Hill, K | 1 |
| Ratnasingam, S | 1 |
| Schwarer, A | 1 |
| Manos, K | 1 |
| Shorten, S | 1 |
| Ng, M | 1 |
| Nelson, N | 1 |
| Xin, L | 1 |
| De Mel Widanalage, S | 1 |
| Sunny, T | 1 |
| Purtill, D | 1 |
| Poon, M | 1 |
| Johnston, A | 1 |
| Cochrane, T | 1 |
| Lee, HP | 1 |
| Hapgood, G | 1 |
| Tam, C | 1 |
| Opat, S | 1 |
| Hawkes, E | 1 |
| Seymour, J | 1 |
| Cheah, CY | 1 |
| Eroglu, C | 1 |
| Kaynar, L | 1 |
| Orhan, O | 1 |
| Keklik, M | 1 |
| Sahin, C | 1 |
| Yildiz, OG | 1 |
| Mentes, S | 1 |
| Kurnaz, F | 1 |
| Aslan, D | 1 |
| Sivgin, S | 1 |
| Soyuer, S | 1 |
| Eser, B | 1 |
| Cetin, M | 1 |
| Unal, A | 1 |
| Czyz, A | 1 |
| Lojko-Dankowska, A | 1 |
| Dytfeld, D | 1 |
| Nowicki, A | 1 |
| Gil, L | 1 |
| Matuszak, M | 1 |
| Kozlowska-Skrzypczak, M | 1 |
| Kazmierczak, M | 1 |
| Bembnista, E | 1 |
| Komarnicki, M | 1 |
| Sobol, U | 1 |
| Rodriguez, T | 1 |
| Smith, S | 1 |
| Go, A | 1 |
| Vimr, R | 1 |
| Parthasarathy, M | 1 |
| Guo, R | 1 |
| Stiff, P | 1 |
| Brem, S | 3 |
| Meyers, CA | 1 |
| Palmer, G | 1 |
| Booth-Jones, M | 1 |
| Jain, S | 1 |
| Ewend, MG | 2 |
| Samis Zella, MA | 1 |
| Wallocha, M | 1 |
| Slotty, PJ | 1 |
| Isik, G | 1 |
| Hänggi, D | 1 |
| Schroeteler, J | 1 |
| Ewelt, C | 1 |
| Steiger, HJ | 1 |
| Sabel, M | 1 |
| Kothari, J | 1 |
| Peggs, KS | 1 |
| Bird, A | 1 |
| Thomson, KJ | 1 |
| Morris, E | 1 |
| Virchis, AE | 1 |
| Lambert, J | 1 |
| Goldstone, AH | 1 |
| Linch, DC | 1 |
| Ardeshna, KM | 1 |
| Aoki, T | 1 |
| Nishikawa, R | 1 |
| Sugiyama, K | 1 |
| Nonoguchi, N | 1 |
| Kawabata, N | 1 |
| Mishima, K | 1 |
| Adachi, J | 1 |
| Kurisu, K | 1 |
| Yamasaki, F | 1 |
| Tominaga, T | 1 |
| Ueki, K | 1 |
| Higuchi, F | 1 |
| Yamamoto, T | 2 |
| Ishikawa, E | 1 |
| Takeshima, H | 1 |
| Yamashita, S | 1 |
| Arita, K | 1 |
| Hirano, H | 1 |
| Yamada, S | 1 |
| Matsutani, M | 1 |
| Sai, K | 1 |
| Zhong, MG | 1 |
| Chen, YS | 1 |
| Mou, YG | 1 |
| Ke, C | 1 |
| Zhang, XH | 1 |
| Yang, QY | 1 |
| Lin, FH | 1 |
| Guo, CC | 1 |
| Chen, ZH | 1 |
| Zeng, J | 1 |
| Lv, YC | 1 |
| Li, X | 1 |
| Gao, WC | 1 |
| Chen, ZP | 1 |
| Mack, F | 1 |
| Schäfer, N | 1 |
| Kebir, S | 1 |
| Stuplich, M | 1 |
| Schaub, C | 1 |
| Niessen, M | 1 |
| Scheffler, B | 1 |
| Herrlinger, U | 1 |
| Glas, M | 1 |
| Rahman, R | 1 |
| Hempfling, K | 1 |
| Norden, AD | 1 |
| Reardon, DA | 2 |
| Nayak, L | 1 |
| Rinne, ML | 1 |
| Beroukhim, R | 1 |
| Doherty, L | 1 |
| Ruland, S | 1 |
| Rai, A | 1 |
| Rifenburg, J | 1 |
| LaFrankie, D | 1 |
| Alexander, BM | 1 |
| Huang, RY | 1 |
| Wen, PY | 1 |
| Lee, EQ | 1 |
| El-Najjar, I | 1 |
| Boumendil, A | 1 |
| Luan, JJ | 1 |
| Thomson, K | 1 |
| Mohty, M | 1 |
| Colombat, P | 2 |
| Biron, P | 1 |
| Tilly, H | 1 |
| Pfreundschuh, M | 2 |
| Cordonnier, C | 1 |
| Sureda, A | 2 |
| Cahn, JY | 1 |
| Vernant, JP | 1 |
| Gribben, J | 1 |
| Cook, G | 1 |
| Haynes, AP | 1 |
| Ferrant, A | 1 |
| Finel, H | 1 |
| Montoto, S | 2 |
| Dreger, P | 3 |
| Nagai, H | 1 |
| Garfin, PM | 1 |
| Link, MP | 1 |
| Donaldson, SS | 1 |
| Advani, RH | 1 |
| Luna-Fineman, S | 1 |
| Kharbanda, S | 1 |
| Porteus, M | 1 |
| Weinberg, KI | 1 |
| Agarwal-Hashmi, R | 1 |
| Venur, VA | 1 |
| Peereboom, DM | 1 |
| Ahluwalia, MS | 1 |
| Chowdhary, SA | 1 |
| Ryken, T | 1 |
| Newton, HB | 1 |
| Nakase, K | 1 |
| Matsuda, R | 1 |
| Nishimura, F | 1 |
| Nakamura, M | 1 |
| Motoyama, Y | 1 |
| Park, YS | 1 |
| Nakase, H | 1 |
| Strowd, RE | 1 |
| Abuali, I | 1 |
| Ye, X | 1 |
| Lu, Y | 1 |
| Grossman, SA | 4 |
| Jungk, C | 1 |
| Chatziaslanidou, D | 1 |
| Ahmadi, R | 1 |
| Capper, D | 1 |
| Bermejo, JL | 1 |
| Exner, J | 1 |
| von Deimling, A | 1 |
| Herold-Mende, C | 1 |
| Unterberg, A | 1 |
| Shimato, S | 1 |
| Nishizawa, T | 1 |
| Ohshima, T | 1 |
| Imai, T | 1 |
| Goto, S | 1 |
| Kato, K | 1 |
| Hohloch, K | 1 |
| Zeynalova, S | 1 |
| Chapuy, B | 1 |
| Loeffler, M | 1 |
| Ziepert, M | 1 |
| Feller, AC | 1 |
| Trümper, L | 1 |
| Hasenclever, D | 1 |
| Wulf, G | 1 |
| Schmitz, N | 4 |
| Hart, MG | 2 |
| Grant, R | 2 |
| Garside, R | 2 |
| Rogers, G | 2 |
| Somerville, M | 2 |
| Stein, K | 2 |
| Finlay, JL | 2 |
| Dhall, G | 1 |
| Boyett, JM | 3 |
| Dunkel, IJ | 2 |
| Gardner, SL | 1 |
| Goldman, S | 2 |
| Yates, AJ | 1 |
| Rosenblum, MK | 1 |
| Stanley, P | 1 |
| Zimmerman, RA | 1 |
| Wallace, D | 1 |
| Pollack, IF | 1 |
| Packer, RJ | 1 |
| van den Bent, MJ | 1 |
| Brandes, AA | 5 |
| Rampling, R | 1 |
| Kouwenhoven, MC | 1 |
| Kros, JM | 1 |
| Carpentier, AF | 1 |
| Clement, PM | 1 |
| Frenay, M | 1 |
| Campone, M | 1 |
| Baurain, JF | 1 |
| Armand, JP | 1 |
| Taphoorn, MJ | 1 |
| Tosoni, A | 3 |
| Kletzl, H | 1 |
| Klughammer, B | 1 |
| Lacombe, D | 1 |
| Gorlia, T | 1 |
| Asthagiri, AR | 1 |
| Baggenstos, M | 1 |
| Lonser, RR | 1 |
| Winter, JN | 1 |
| Inwards, DJ | 1 |
| Spies, S | 1 |
| Wiseman, G | 1 |
| Patton, D | 1 |
| Erwin, W | 1 |
| Rademaker, AW | 2 |
| Weitner, BB | 1 |
| Williams, SF | 1 |
| Tallman, MS | 1 |
| Micallef, I | 1 |
| Mehta, J | 1 |
| Singhal, S | 1 |
| Evens, AM | 1 |
| Zimmer, M | 1 |
| Molina, A | 2 |
| White, CA | 1 |
| Gordon, LI | 1 |
| Coulibaly, B | 1 |
| Nanni, I | 1 |
| Fina, F | 1 |
| Eudes, N | 1 |
| Giorgi, R | 1 |
| Barrie, M | 1 |
| Fuentes, S | 1 |
| Dufour, H | 1 |
| Ouafik, L | 1 |
| Figarella-Branger, D | 1 |
| Kosteljanetz, M | 1 |
| Poulsen, HS | 1 |
| Balossier, A | 1 |
| Dörner, L | 2 |
| Emery, E | 1 |
| Heese, O | 1 |
| Mehdorn, HM | 3 |
| Singh, J | 1 |
| Arai, S | 1 |
| Letsinger, R | 1 |
| Wong, RM | 1 |
| Johnston, LJ | 1 |
| Laport, GG | 1 |
| Lowsky, R | 1 |
| Miklos, DB | 1 |
| Shizuru, JA | 1 |
| Weng, WK | 1 |
| Lavori, PW | 1 |
| Blume, KG | 1 |
| Negrin, RS | 1 |
| Horning, SJ | 1 |
| Mihaliak, AM | 1 |
| Gilbert, CA | 1 |
| Li, L | 1 |
| Daou, MC | 1 |
| Moser, RP | 1 |
| Reeves, A | 1 |
| Cochran, BH | 1 |
| Ross, AH | 1 |
| Kunwar, S | 1 |
| Chang, S | 1 |
| Westphal, M | 3 |
| Vogelbaum, M | 1 |
| Sampson, J | 2 |
| Barnett, G | 1 |
| Shaffrey, M | 1 |
| Ram, Z | 1 |
| Piepmeier, J | 1 |
| Prados, M | 2 |
| Croteau, D | 1 |
| Pedain, C | 1 |
| Leland, P | 1 |
| Husain, SR | 1 |
| Joshi, BH | 1 |
| Puri, RK | 1 |
| Della Puppa, A | 1 |
| Rossetto, M | 1 |
| Ciccarino, P | 1 |
| Del Moro, G | 1 |
| Rotilio, A | 2 |
| Manara, R | 1 |
| Paola Gardiman, M | 1 |
| Denaro, L | 1 |
| d'Avella, D | 2 |
| Scienza, R | 1 |
| Rusthoven, KE | 1 |
| Olsen, C | 1 |
| Franklin, W | 1 |
| Kleinschmidt-DeMasters, BK | 1 |
| Kavanagh, BD | 1 |
| Gaspar, LE | 1 |
| Lillehei, K | 1 |
| Waziri, A | 1 |
| Damek, DM | 1 |
| Chen, C | 1 |
| Nagaiah, G | 1 |
| Almubarak, M | 1 |
| Khan, M | 1 |
| Altaha, R | 1 |
| Figueiredo, EG | 1 |
| Faria, JW | 1 |
| Teixeira, MJ | 1 |
| Cohnen, J | 1 |
| Keric, N | 1 |
| Kantelhardt, SR | 1 |
| Giese, A | 2 |
| Muntasser, H | 1 |
| Liaquat, I | 1 |
| Barlow, A | 1 |
| Whittle, I | 1 |
| Márquez-Rivas, J | 1 |
| Rivero-Garvía, M | 1 |
| Mayorga-Buiza, MJ | 1 |
| Villa, D | 1 |
| Seshadri, T | 1 |
| Puig, N | 1 |
| Massey, C | 1 |
| Tsang, R | 1 |
| Keating, A | 1 |
| Crump, M | 2 |
| Kuruvilla, J | 1 |
| Vauleon, E | 1 |
| Mesbah, H | 1 |
| Gedouin, D | 1 |
| Lecouillard, I | 1 |
| Louvel, G | 1 |
| Hamlat, A | 1 |
| Riffaud, L | 1 |
| Carsin, B | 1 |
| Quillien, V | 1 |
| Audrain, O | 1 |
| Lesimple, T | 1 |
| DellaPuppa, A | 1 |
| De Bonis, P | 1 |
| Anile, C | 1 |
| Pompucci, A | 1 |
| Fiorentino, A | 1 |
| Balducci, M | 1 |
| Chiesa, S | 1 |
| Maira, G | 1 |
| Mangiola, A | 1 |
| Kuhnhenn, J | 1 |
| Kowalski, T | 1 |
| Steenken, S | 1 |
| Ostermann, K | 1 |
| Schlegel, U | 1 |
| Chamberlain, MC | 1 |
| Watts, C | 1 |
| Dunn, L | 1 |
| Ashkan, K | 1 |
| Jenkinson, M | 1 |
| Smith, P | 1 |
| Matthews, J | 1 |
| Greaves, P | 1 |
| Lillington, D | 1 |
| Anderson, D | 1 |
| Gribben, JG | 1 |
| Lister, TA | 1 |
| Mustafa, A | 1 |
| Rohr, A | 1 |
| Nabavi, A | 1 |
| Pizer, B | 1 |
| Salehzadeh, A | 1 |
| Brodbelt, A | 1 |
| Mallucci, C | 1 |
| Afra, D | 1 |
| Sipos, L | 1 |
| Vitanovics, D | 1 |
| Arellano-Rodrigo, E | 1 |
| López-Guillermo, A | 1 |
| Bessell, EM | 1 |
| Nomdedeu, B | 1 |
| Montserrat, E | 1 |
| Graus, F | 1 |
| Hammoud, DA | 1 |
| Belden, CJ | 1 |
| Ho, AC | 1 |
| Dal Pan, GJ | 1 |
| Herskovits, EH | 1 |
| Hilt, DC | 1 |
| Brem, H | 7 |
| Pomper, MG | 1 |
| Friedman, HS | 4 |
| Keir, ST | 1 |
| Houghton, PJ | 1 |
| Olivi, A | 6 |
| Tatter, S | 1 |
| Barker, F | 1 |
| Judy, K | 2 |
| Olsen, J | 1 |
| Bruce, J | 2 |
| Hilt, D | 3 |
| Fisher, J | 1 |
| Piantadosi, S | 2 |
| Lamszus, K | 1 |
| Rojas-Marcos, I | 1 |
| Calvet, D | 1 |
| Janoray, P | 1 |
| Delattre, JY | 1 |
| Abrey, LE | 1 |
| Moskowitz, CH | 1 |
| Mason, WP | 1 |
| Stewart, D | 1 |
| Forsyth, P | 1 |
| Paleologos, N | 1 |
| Correa, DD | 1 |
| Anderson, ND | 1 |
| Caron, D | 1 |
| Zelenetz, A | 1 |
| Nimer, SD | 1 |
| DeAngelis, LM | 1 |
| Guerin, C | 1 |
| Weingart, JD | 1 |
| Lawson, HC | 2 |
| Prados, MD | 1 |
| Yung, WK | 2 |
| Fine, HA | 1 |
| Greenberg, HS | 2 |
| Junck, L | 1 |
| Chang, SM | 1 |
| Nicholas, MK | 1 |
| Robins, HI | 1 |
| Mehta, MP | 2 |
| Fink, KL | 1 |
| Jaeckle, KA | 1 |
| Kuhn, J | 1 |
| Hess, KR | 1 |
| Schold, SC | 3 |
| Kucinski, T | 1 |
| Knopp, U | 1 |
| Goldbrunner, R | 1 |
| Hamel, W | 1 |
| Tonn, JC | 1 |
| Kleinberg, LR | 2 |
| Weingart, J | 3 |
| Burger, P | 1 |
| Carson, K | 1 |
| Li, K | 1 |
| Wharam, MD | 1 |
| Rosenthal, MA | 1 |
| Ashley, DL | 1 |
| Cher, L | 1 |
| Quinn, JA | 2 |
| Friedman, AH | 3 |
| Rich, JN | 2 |
| Sampson, JH | 1 |
| Vredenburgh, J | 1 |
| Gururangan, S | 1 |
| Provenzale, JM | 2 |
| Walker, A | 1 |
| Schweitzer, H | 1 |
| Bigner, DD | 2 |
| Tourt-Uhlig, S | 2 |
| Herndon, JE | 2 |
| Affronti, ML | 1 |
| Jackson, S | 1 |
| Allen, D | 1 |
| Ziegler, K | 1 |
| Bohlin, C | 1 |
| Lentz, C | 1 |
| Amistà, P | 3 |
| Nicolardi, L | 2 |
| Grosso, D | 1 |
| Berti, F | 2 |
| Ermani, M | 2 |
| Saito, R | 1 |
| Bringas, J | 1 |
| Mirek, H | 1 |
| Berger, MS | 1 |
| Bankiewicz, KS | 1 |
| Basso, U | 2 |
| Reni, M | 1 |
| Valduga, F | 1 |
| Monfardini, S | 2 |
| Sotti, G | 1 |
| Vordermark, D | 1 |
| Kölbl, O | 1 |
| Josting, A | 3 |
| Sieniawski, M | 1 |
| Glossmann, JP | 1 |
| Staak, O | 1 |
| Nogova, L | 1 |
| Peters, N | 1 |
| Mapara, M | 1 |
| Dörken, B | 1 |
| Ko, Y | 1 |
| Metzner, B | 2 |
| Kisro, J | 1 |
| Diehl, V | 4 |
| Engert, A | 3 |
| Webster, M | 1 |
| Cairncross, G | 1 |
| Gertler, S | 1 |
| Perry, J | 1 |
| Wainman, N | 2 |
| Eisenhauer, E | 2 |
| Tsao, MN | 1 |
| Whelan, TJ | 1 |
| Morris, DE | 1 |
| Hayman, JA | 1 |
| Flickinger, JC | 1 |
| Mills, M | 1 |
| Rogers, CL | 1 |
| Souhami, L | 1 |
| Park, MC | 2 |
| Weaver, CE | 1 |
| Donahue, JE | 1 |
| Sampath, P | 2 |
| Wong, RP | 1 |
| Baetz, T | 1 |
| Krahn, MJ | 1 |
| Biagi, J | 1 |
| Ducray, F | 1 |
| Colin, P | 1 |
| Cartalat-Carel, S | 1 |
| Pelissou-Guyotat, I | 1 |
| Mahla, K | 1 |
| Audra, P | 1 |
| Gaucherand, P | 1 |
| Honnorat, J | 1 |
| Trouillas, P | 1 |
| Hagberg, H | 2 |
| Gisselbrecht, C | 2 |
| Maciá Escalante, S | 1 |
| Rodríguez Lescure, A | 1 |
| Segura Ibáñez, JM | 1 |
| Sáez Castán, J | 1 |
| Guillén Ponce, C | 1 |
| Carrato Mena, A | 1 |
| Bohan, E | 1 |
| Hussain, N | 1 |
| Kleinberg, L | 1 |
| Carson, KA | 1 |
| Fisher, JD | 1 |
| Delaney, SM | 1 |
| Rosenblum, ML | 1 |
| Tatter, SB | 1 |
| Dolan, ME | 2 |
| Atta, J | 1 |
| Chow, KU | 1 |
| Weidmann, E | 1 |
| Mitrou, PS | 1 |
| Hoelzer, D | 1 |
| Martin, H | 1 |
| Gallego, JM | 1 |
| Barcia, JA | 1 |
| Barcia-Mariño, C | 1 |
| Blumenfeld, Z | 1 |
| Benaroush, M | 1 |
| Zuckerman, T | 1 |
| Gilbert, M | 1 |
| Goodkin, R | 1 |
| Penar, PL | 1 |
| Varia, M | 1 |
| Cush, S | 1 |
| Carey, LA | 1 |
| Al-Ali, HK | 1 |
| Wittekind, C | 1 |
| Niederwieser, D | 1 |
| Krishnan, A | 1 |
| Nademanee, A | 1 |
| Fung, HC | 1 |
| Raubitschek, AA | 1 |
| Yamauchi, D | 1 |
| Rodriguez, R | 1 |
| Spielberger, RT | 1 |
| Falk, P | 1 |
| Palmer, JM | 1 |
| Forman, SJ | 1 |
| Benekli, M | 1 |
| Smiley, SL | 1 |
| Younis, T | 1 |
| Czuczman, MS | 1 |
| Hernandez-Ilizaliturri, F | 1 |
| Bambach, B | 1 |
| Battiwalla, M | 1 |
| Padmanabhan, S | 1 |
| McCarthy, PL | 1 |
| Hahn, T | 1 |
| Kyriakou, C | 1 |
| Canals, C | 1 |
| Goldstone, A | 1 |
| Caballero, D | 1 |
| Kobbe, G | 1 |
| Kolb, HJ | 1 |
| Kienast, J | 1 |
| Reimer, P | 1 |
| Finke, J | 1 |
| Oberg, G | 1 |
| Hunter, A | 1 |
| Theorin, N | 1 |
| Darakchiev, BJ | 1 |
| Albright, RE | 2 |
| Breneman, JC | 1 |
| Warnick, RE | 1 |
| Gill, P | 1 |
| Litzow, M | 1 |
| Buckner, J | 1 |
| Arndt, C | 1 |
| Moynihan, T | 1 |
| Christianson, T | 1 |
| Ansell, S | 1 |
| Galanis, E | 1 |
| Lin, SH | 1 |
| Mortimer, JE | 1 |
| Hewlett, JS | 1 |
| Bay, J | 1 |
| Livingston, RB | 1 |
| Evans, RG | 1 |
| Burgert, EO | 1 |
| Gilchrist, GS | 1 |
| Smithson, WA | 1 |
| Pritchard, DJ | 1 |
| Bruckman, JE | 1 |
| Lieberman, AN | 1 |
| Foo, SH | 1 |
| Ransohoff, J | 2 |
| Wise, A | 1 |
| George, A | 1 |
| Gordon, W | 1 |
| Walker, R | 1 |
| Salcman, M | 1 |
| Kaplan, RS | 1 |
| Ducker, TB | 1 |
| Abdo, H | 1 |
| Montgomery, E | 1 |
| Vincent, FM | 1 |
| Kapp, JP | 1 |
| Vance, R | 1 |
| Hill, GJ | 1 |
| Krementz, ET | 1 |
| Hill, HZ | 1 |
| Bremer, AM | 2 |
| Nguyen, TQ | 1 |
| Balsys, R | 1 |
| Somló, P | 2 |
| Révész, T | 2 |
| Cascino, TL | 2 |
| Byrne, TN | 1 |
| Deck, MD | 1 |
| Posner, JB | 1 |
| Queisser, W | 1 |
| Schnitzler, G | 1 |
| Heim, ME | 2 |
| König, H | 1 |
| Katz, R | 1 |
| Fritze, D | 1 |
| Herrmann, R | 1 |
| Arnold, H | 1 |
| Henss, H | 1 |
| Trux, F | 1 |
| Gropp, C | 1 |
| Havemann, K | 1 |
| Jamieson, GG | 1 |
| Gill, PG | 1 |
| Levin, VA | 2 |
| Wilson, CB | 3 |
| Vestnys, PS | 1 |
| Eagan, RT | 1 |
| Dinapoli, RP | 1 |
| Hermann, RC | 1 |
| Groover, RV | 1 |
| Layton, DD | 1 |
| Scott, M | 1 |
| Casotto, A | 1 |
| Buoncristiani, P | 1 |
| Ghanta, VK | 1 |
| Hiramoto, RN | 1 |
| Davis, DW | 1 |
| Hiramoto, NS | 1 |
| Ogawa, M | 1 |
| Mukaiyama, T | 1 |
| Herrmann, JJ | 1 |
| Roenigk, HH | 1 |
| Hurria, A | 1 |
| Kuzel, TM | 1 |
| Samuelson, E | 1 |
| Rosen, ST | 1 |
| Burger, PC | 4 |
| Walker, M | 1 |
| Selker, R | 1 |
| Vick, NA | 3 |
| Black, K | 1 |
| Sisti, M | 2 |
| Mohr, G | 1 |
| Buckner, JC | 1 |
| Brown, LD | 1 |
| Kugler, JW | 1 |
| Krook, JE | 1 |
| Mailliard, JA | 1 |
| Kardinal, CG | 1 |
| Tschetter, LK | 1 |
| O'Fallon, JR | 1 |
| Scheithauer, BW | 1 |
| Aabo, K | 2 |
| Vindeløv, LL | 2 |
| Christensen, IJ | 1 |
| Spang-Thomsen, M | 2 |
| Kremens, B | 1 |
| Klingebiel, T | 1 |
| Herrmann, F | 1 |
| Bender-Götze, C | 1 |
| Burdach, S | 1 |
| Ebell, W | 1 |
| Friedrich, W | 1 |
| Koscielniak, E | 1 |
| Schmid, H | 1 |
| Siegert, W | 1 |
| Glass, B | 2 |
| Haferlach, T | 1 |
| Horst, HA | 1 |
| Ollech-Chwoyka, J | 1 |
| Suttorp, M | 1 |
| Gassmann, W | 1 |
| Löffler, H | 1 |
| Kitchell, BE | 1 |
| Brown, DM | 1 |
| Luck, EE | 1 |
| Woods, LL | 1 |
| Orenberg, EK | 1 |
| Bloch, DA | 1 |
| Roed, H | 1 |
| Haas, R | 1 |
| Moos, M | 1 |
| Möhle, R | 1 |
| Döhner, H | 1 |
| Witt, B | 1 |
| Goldschmidt, H | 1 |
| Murea, S | 1 |
| Flentje, M | 1 |
| Wannenmacher, M | 1 |
| Hunstein, W | 1 |
| Bierman, PJ | 1 |
| Anderson, JR | 1 |
| Freeman, MB | 1 |
| Vose, JM | 1 |
| Kessinger, A | 2 |
| Bishop, MR | 1 |
| Armitage, JO | 2 |
| Allen, JC | 1 |
| Siffert, J | 1 |
| Boiardi, A | 3 |
| Silvani, A | 3 |
| Pozzi, A | 2 |
| Farinotti, M | 1 |
| Fariselli, L | 1 |
| Broggi, G | 3 |
| Salmaggi, A | 3 |
| Scelzi, E | 1 |
| Zampieri, P | 1 |
| Rigon, A | 1 |
| Fiorentino, MV | 1 |
| Varterasian, M | 1 |
| Janakiraman, N | 1 |
| Karanes, C | 1 |
| Abella, E | 1 |
| Uberti, J | 1 |
| Dragovic, J | 1 |
| Raman, SB | 1 |
| al-Katib, A | 1 |
| Du, W | 1 |
| Silver, SM | 1 |
| Adams, PT | 1 |
| Sensenbrenner, L | 1 |
| Ratanatharathorn, V | 1 |
| Hildebrand, J | 1 |
| De Witte, O | 1 |
| Sahmoud, T | 1 |
| Johnston, SR | 1 |
| Constenla, DO | 1 |
| Moore, J | 1 |
| Atkinson, H | 1 |
| A'Hern, RP | 1 |
| Dadian, G | 1 |
| Riches, PG | 1 |
| Gore, ME | 1 |
| Cagnoni, PJ | 1 |
| Nieto, Y | 1 |
| Shpall, EJ | 1 |
| Bearman, SI | 1 |
| Barón, AE | 1 |
| Ross, M | 1 |
| Matthes, S | 1 |
| Dunbar, SE | 1 |
| Jones, RB | 1 |
| Kàtay, I | 1 |
| Rueffer, U | 2 |
| Winter, S | 1 |
| Tesch, H | 3 |
| Wickramanayake, PD | 2 |
| Guruangan, S | 1 |
| Garvin, JH | 1 |
| Rosenblum, M | 1 |
| Gardner, S | 1 |
| Merchant, TE | 1 |
| Gollamudi, S | 1 |
| Williams, D | 1 |
| Subach, BR | 1 |
| Witham, TF | 1 |
| Kondziolka, D | 1 |
| Lunsford, LD | 1 |
| Bozik, M | 1 |
| Schiff, D | 1 |
| Papadopoulos, KP | 1 |
| Balmaceda, C | 1 |
| Fetell, M | 1 |
| Kaufman, E | 1 |
| Vahdat, LT | 1 |
| Isaacson, S | 1 |
| De LaPaz, R | 1 |
| Savage, DG | 1 |
| Troxel, A | 1 |
| Antman, KH | 1 |
| Hesdorffer, CS | 1 |
| Prager, JM | 1 |
| Grenier, Y | 1 |
| Cozzens, JW | 2 |
| Chiowanich, P | 1 |
| Gorey, MT | 1 |
| Meyer, JR | 1 |
| Bogart, JA | 1 |
| Ungureanu, C | 1 |
| Ryu, S | 1 |
| Chung, CT | 1 |
| Zamkoff, KW | 1 |
| Reiser, M | 1 |
| Draube, A | 1 |
| Söhngen, D | 1 |
| Wolf, J | 2 |
| Engelhard, HH | 1 |
| Vlassenko, AG | 1 |
| Thiessen, B | 1 |
| Beattie, BJ | 1 |
| Malkin, MG | 1 |
| Blasberg, RG | 1 |
| Berglund, A | 1 |
| Enblad, G | 1 |
| Carlson, K | 1 |
| Glimelius, B | 1 |
| Eoli, M | 2 |
| Pluda, J | 1 |
| Ewesuedo, RB | 1 |
| Long, L | 1 |
| Cokgor, I | 1 |
| Colvin, OM | 1 |
| Haglund, MM | 1 |
| Ashley, DM | 1 |
| Pegg, AE | 1 |
| Moschel, RC | 1 |
| McLendon, RE | 1 |
| Stewart, ES | 1 |
| Garcia-Turner, AM | 1 |
| Pollo, B | 1 |
| Milanesi, I | 1 |
| Palmisano, V | 1 |
| Pasetto, LM | 1 |
| Fiorillo, A | 1 |
| Maggi, G | 1 |
| Martone, A | 1 |
| Migliorati, R | 1 |
| D'Amore, R | 1 |
| Alfieri, E | 1 |
| Greco, N | 1 |
| Cirillo, S | 1 |
| Marano, I | 1 |
| Seyfarth, B | 1 |
| Kuse, R | 1 |
| Sonnen, R | 1 |
| Chen, YQ | 1 |
| Linassier, C | 1 |
| Destrieux, C | 1 |
| Benboubker, L | 1 |
| Alcaraz, L | 1 |
| Bergemer-Fouquet, AM | 1 |
| Jan, M | 1 |
| Calais, G | 1 |
| Weihrauch, MR | 1 |
| Re, D | 1 |
| Scheidhauer, K | 1 |
| Ansén, S | 1 |
| Dietlein, M | 1 |
| Bischoff, S | 1 |
| Bohlen, H | 1 |
| Schicha, H | 1 |
| Cornely, OA | 1 |
| Pels, H | 1 |
| Bethe, U | 1 |
| Seibold, M | 1 |
| Toepelt, K | 1 |
| Soehngen, D | 1 |
| Ritzkowsky, A | 1 |
| Becherer, A | 1 |
| Mitterbauer, M | 1 |
| Jaeger, U | 1 |
| Kalhs, P | 1 |
| Greinix, HT | 1 |
| Karanikas, G | 1 |
| Pötzi, C | 1 |
| Raderer, M | 1 |
| Dudczak, R | 1 |
| Kletter, K | 1 |
| Stephens, RL | 1 |
| Hoogstraten, B | 1 |
| Haas, C | 1 |
| Clark, G | 1 |
| Sumer, T | 1 |
| Freeman, AI | 2 |
| Cohen, M | 1 |
| Thomas, PR | 1 |
| Sinks, LF | 2 |
| Lieberman, A | 1 |
| Giles, GR | 1 |
| Lawton, JO | 1 |
| Salmon, SE | 1 |
| Lynch, RG | 1 |
| Medoff, G | 1 |
| Valeriote, F | 1 |
| Calogero, J | 1 |
| Crafts, DC | 1 |
| Boldrey, EB | 1 |
| Rosenberg, A | 1 |
| Enot, KJ | 1 |
| Carter, SK | 1 |
| Watne, K | 3 |
| Hannisdal, E | 1 |
| Nome, O | 1 |
| Hager, B | 3 |
| Hirschberg, H | 2 |
| Bradac, GB | 1 |
| Soffietti, R | 1 |
| Riva, A | 1 |
| Stura, G | 1 |
| Sales, S | 1 |
| Schiffer, D | 1 |
| Harding, M | 1 |
| Selby, P | 1 |
| Gore, M | 1 |
| Perren, T | 1 |
| Treleavan, J | 1 |
| Mansi, J | 1 |
| Zulian, G | 1 |
| Milan, S | 1 |
| Meldrum, M | 1 |
| Viner, C | 1 |
| Saba, HI | 2 |
| Cruse, CW | 2 |
| Wells, KE | 2 |
| Klein, CJ | 2 |
| Reintgen, DS | 2 |
| Meloni, G | 1 |
| Vignetti, M | 1 |
| De Fabritiis, P | 1 |
| Petti, MC | 1 |
| Pinto, MR | 1 |
| Testi, AM | 1 |
| Vegna, ML | 1 |
| Mandelli, F | 1 |
| Brice, P | 1 |
| Ferme, C | 1 |
| Lepage, E | 1 |
| Baruchel, A | 1 |
| Gerota, O | 1 |
| Boiron, M | 1 |
| Hurd, DD | 1 |
| Haake, RJ | 1 |
| Lasky, LC | 1 |
| Christiansen, NP | 1 |
| McGlave, PB | 1 |
| Bostrom, B | 1 |
| Levine, EG | 1 |
| Weisdorf, DJ | 1 |
| Kim, TH | 1 |
| Peterson, BA | 1 |
| Mahaley, MS | 2 |
| Black, KL | 1 |
| Ciric, IS | 1 |
| Eller, TW | 1 |
| Rogers, LR | 2 |
| Purvis, JB | 1 |
| Lederman, RJ | 2 |
| Rosenbloom, SA | 1 |
| Tomsak, RL | 2 |
| Estes, ML | 1 |
| Magdinec, M | 1 |
| Medendorp, SV | 1 |
| Recht, L | 1 |
| Fram, RJ | 1 |
| Strauss, G | 1 |
| Fitzgerald, TJ | 1 |
| Liepman, M | 1 |
| Lew, R | 1 |
| Kadish, S | 1 |
| Sherman, D | 1 |
| Wilson, J | 1 |
| Greenberger, J | 1 |
| Zackheim, HS | 1 |
| Epstein, EH | 1 |
| Crain, WR | 1 |
| Rodriguez, L | 1 |
| Chamberlain, M | 1 |
| Silver, P | 1 |
| Levin, V | 1 |
| Zamorano, L | 1 |
| Katanick, D | 1 |
| Dujovny, M | 1 |
| Yakar, D | 1 |
| Malik, G | 1 |
| Ausman, JI | 1 |
| Jagannath, S | 1 |
| Dicke, KA | 1 |
| Tucker, SL | 1 |
| Velasquez, WS | 1 |
| Smith, K | 1 |
| Vaughan, WP | 1 |
| Horwitz, LJ | 1 |
| Hagemeister, FB | 1 |
| Harris, MI | 1 |
| Bruner, JM | 1 |
| Feun, LG | 1 |
| Miller, DF | 1 |
| Bay, JW | 1 |
| Purvis, JD | 1 |
| Ensminger, WD | 1 |
| Layton, PB | 1 |
| Gebarski, S | 1 |
| Meyer, M | 1 |
| Chaffee, B | 1 |
| Bender, JF | 1 |
| Grillo-Lopez, AJ | 1 |
| DeLong, ER | 1 |
| Bullard, DE | 1 |
| Khandekar, JD | 1 |
| Cairncross, JG | 1 |
| Papavero, L | 1 |
| Loew, F | 1 |
| Jaksche, H | 1 |
| Hughes, EN | 1 |
| Shillito, J | 1 |
| Sallan, SE | 1 |
| Loeffler, JS | 1 |
| Cassady, JR | 1 |
| Tarbell, NJ | 1 |
| Di Chiro, G | 1 |
| Oldfield, E | 1 |
| Wright, DC | 1 |
| De Michele, D | 1 |
| Katz, DA | 1 |
| Patronas, NJ | 1 |
| Doppman, JL | 1 |
| Larson, SM | 1 |
| Ito, M | 1 |
| Kufta, CV | 1 |
| Cavo, M | 1 |
| Galieni, P | 1 |
| Tassi, C | 1 |
| Gobbi, M | 1 |
| Tura, S | 1 |
| Heros, DO | 1 |
| Renkens, K | 1 |
| Kasdon, DL | 2 |
| Adelman, LS | 1 |
| Appelbaum, FR | 1 |
| Buckner, CD | 1 |
| Levi, JA | 1 |
| Fox, RM | 1 |
| Tattersall, MH | 1 |
| Woods, RL | 1 |
| Thomson, D | 1 |
| Gill, G | 1 |
| Abdi, EA | 1 |
| Hanson, J | 1 |
| McPherson, TA | 1 |
| Johnson, DW | 1 |
| Parkinson, D | 1 |
| Wolpert, SM | 1 |
| Kwan, ES | 1 |
| Laucella, M | 1 |
| Anderson, ML | 1 |
| Minton, JP | 1 |
| Peck, GL | 1 |
| Sachatello, C | 1 |
| Gaeta, J | 1 |
| Shah, NK | 1 |
| Wang, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Multicenter, Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer[NCT00525590] | Phase 2 | 69 participants (Actual) | Interventional | 2007-12-12 | Completed | ||
| Prospective and Retrospective Memory Perception Assessment in Central/Non-central Nervous System Cancers[NCT03975959] | 420 participants (Anticipated) | Interventional | 2019-05-10 | Recruiting | |||
| Randomized Phase II of TARCEVA™ (Erlotinib) Versus Temozolomide Or BCNU in Patients With Recurrent Glioblastoma Multiforme[NCT00086879] | Phase 2 | 110 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Gemcitabine and High-dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease[NCT00388349] | Phase 2 | 146 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study[NCT04066920] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-01 | Not yet recruiting | ||
| PHASE I, OPEN LABEL, MULTICENTER DOSE ESCALATION STUDY OF GLIADEL IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA[NCT00004028] | Phase 1 | 0 participants | Interventional | 1996-09-30 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| A Phase II， Single-arm Trail of Chidamide Combined With Rituximab and High-dose Methotrexate in Previously Untreated Patients With Primary Central Nervous System Lymphoma[NCT04516655] | Phase 2 | 51 participants (Anticipated) | Interventional | 2020-09-01 | Not yet recruiting | ||
| A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas[NCT00003176] | Phase 2 | 82 participants | Interventional | 1998-03-25 | Completed | ||
| A Phase II Study of SarCNU (NSC 364432) in Patients With Malignant Glioma[NCT00036660] | Phase 2 | 10 participants (Actual) | Interventional | 2002-01-10 | Completed | ||
| A Phase II Study of Second-Line SarCNU (NSC 364432) in Patients With Recurrent/Metastatic Colorectal Cancer[NCT00028015] | Phase 2 | 18 participants (Actual) | Interventional | 2001-10-30 | Completed | ||
| Phase I GLIADEL and Continuous Infusion of Intravenous O6-Benzylguanine Trial in Patients With Recurrent Malignant Glioma[NCT00004892] | Phase 1 | 0 participants | Interventional | 2000-04-30 | Completed | ||
| EUS-Guided Radiofrequency Ablation of Pancreatic Cysts - A Safety and Efficacy Trial[NCT05916846] | 28 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT00359606] | Phase 1 | 58 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Neurologic Death was defined as death due to progression of neurologic disease. (NCT00525590)
Timeframe: Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed)
| Intervention | percentage of participants (Number) |
|---|---|
| GLIADEL | 1.9 |
NF was assessed as the performance of 3 neurocognitive domains:memory(MD),executive function(EFD), fine motor coordination(FMCD). For each domain, z-scores were derived from participant's scores in individual neurocognitive tests using an age-adjusted and education-adjusted normative distribution of scores from an unimpaired population.Individual z-scores from related tests were averaged to determine overall z-score.If a z-score average decreased from baseline by greater than or equal to(>=)3 standard deviations(SD)in tests' normative age-adjusted distribution on 2 consecutive visits or decreased by >=3 SD on last follow-up visit, participant were considered to have significant deterioration in their NF at time of the first decrease in z-score.Deterioration in NF:demonstrated deterioration for at least two of the three neurocognitive domains based on these changes from screening.Rate of deterioration in NF was measured as estimated percentage of participants using Kaplan-Meier method. (NCT00525590)
Timeframe: Month 12
| Intervention | percentage of participants (Number) |
|---|---|
| GLIADEL | 2.8 |
The time to neurocognitive deterioration was defined as the number of days between the date of study treatment and the date of neurocognitive deterioration based on NF assessment. This was assessed using Kaplan Meier method. (NCT00525590)
Timeframe: Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed)
| Intervention | months (Number) |
|---|---|
| GLIADEL | NA |
The correlation between recurrence (local, distant or overall) & NF was assessed by presenting change in NF domain scores (memory domain [MD], executive function domain [EFD], fine motor coordination domain [FMCD]) after tumor recurrence (Visits X, X+1, X+2, and X+3) compared to before tumor recurrence (Visit X-1). Here 'Visit X' refers to visit at which participants had tumor recurrence, Visit X-1 refers to visit immediately before the recurrence and X+1, X+2, X+3 refers to subsequent first, second & third visit after the recurrence.NF domain z-scores were derived from participant's scores in individual neurocognitive tests using an age-adjusted &education-adjusted normative distribution of scores from an unimpaired population. Individual z-scores from related tests were averaged to determine overall z-score for each of NF domains. (NCT00525590)
Timeframe: Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed)
| Intervention | z-score (Mean) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Local Recurrence: MD at Visit (X-1) | Local Recurrence: MD Change at Visit (X-1) | Local Recurrence: MD Change at Visit (X+1) | Local Recurrence: MD Change at Visit (X+2) | Local Recurrence: MD Change at Visit (X+3) | Local Recurrence: EFD at Visit (X-1) | Local Recurrence: EFD Change at Visit (X-1) | Local Recurrence: EFD Change at Visit (X+1) | Local Recurrence: EFD Change at Visit (X+2) | Local Recurrence: EFD Change at Visit (X+3) | Local Recurrence: FMCD at Visit (X-1) | Local Recurrence: FMCD Change at Visit (X-1) | Local Recurrence: FMCD Change at Visit (X+1) | Local Recurrence: FMCD Change at Visit (X+2) | Local Recurrence: FMCD Change at Visit (X+3) | Distant Recurrence: MD at Visit (X-1) | Distant Recurrence: MD Change at Visit (X-1) | Distant Recurrence: MD Change at Visit (X+1) | Distant Recurrence: MD Change at Visit (X+2) | Distant Recurrence: MD Change at Visit (X+3) | Distant Recurrence: EFD at Visit (X-1) | Distant Recurrence: EFD Change at Visit (X-1) | Distant Recurrence: EFD Change at Visit (X+1) | Distant Recurrence: EFD Change at Visit (X+2) | Distant Recurrence: EFD Change at Visit (X+3) | Distant Recurrence: FMCD at Visit (X-1) | Distant Recurrence: FMCD Change at Visit (X-1) | Distant Recurrence: FMCD Change at Visit (X+1) | Distant Recurrence: FMCD Change at Visit (X+2) | Distant Recurrence: FMCD Change at Visit (X+3) | Overall Recurrence: MD at Visit (X-1) | Overall Recurrence: MD Change at Visit (X-1) | Overall Recurrence: MD Change at Visit (X+1) | Overall Recurrence: MD Change at Visit (X+2) | Overall Recurrence: MD Change at Visit (X+3) | Overall Recurrence: EFD at Visit (X-1) | Overall Recurrence: EFD Change at Visit (X-1) | Overall Recurrence: EFD Change at Visit (X+1) | Overall Recurrence: EFD Change at Visit (X+2) | Overall Recurrence: EFD Change at Visit (X+3) | Overall Recurrence: FMCD at Visit (X-1) | Overall Recurrence: FMCD Change at Visit (X-1) | Overall Recurrence: FMCD Change at Visit (X+1) | Overall Recurrence: FMCD Change at Visit (X+2) | Overall Recurrence: FMCD Change at Visit (X+3) | |
| GLIADEL | -0.9 | -1.1 | 0.7 | 0.1 | -0.8 | -0.4 | -0.5 | 0.2 | -0.0 | -1.1 | -1.5 | 0.4 | 0.5 | -0.4 | 0.3 | -1.0 | 0.2 | -0.2 | -0.2 | -0.7 | -0.2 | -0.2 | -0.5 | -0.8 | -0.8 | -1.2 | -0.1 | -0.4 | -1.1 | -0.1 | -0.9 | -0.1 | -0.1 | -0.2 | -0.7 | -0.1 | -0.3 | -0.5 | -0.6 | -0.8 | -1.2 | 0.0 | -0.3 | -0.9 | -0.1 |
Preservation of NF was defined as a decrease of less than or equal to (<=) 1 SD, any increase, or no change (0 SD) in z-score for each domain (memory domain, executive function domain, and fine motor coordination domain). (NCT00525590)
Timeframe: Month 12
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Domains preserved=3 | Domains preserved=2 | Domains preserved=1 | Domains preserved=0 | |
| GLIADEL | 9 | 5 | 0 | 0 |
Preservation of NF was defined as a decrease of <=1 SD, any increase, or no change (0 SD) in z-score for each domain (memory domain, executive function domain, and fine motor coordination domain). (NCT00525590)
Timeframe: Month 2
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Domains preserved=3 | Domains preserved=2 | Domains preserved=1 | Domains preserved=0 | |
| GLIADEL | 26 | 12 | 4 | 3 |
Preservation of NF was defined as a decrease of <=1 SD, any increase, or no change (0 SD) in z-score for each domain (memory domain, executive function domain, and fine motor coordination domain). (NCT00525590)
Timeframe: Month 4
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Domains preserved=3 | Domains preserved=2 | Domains preserved=1 | Domains preserved=0 | |
| GLIADEL | 24 | 9 | 2 | 1 |
Preservation of NF was defined as a decrease of <=1 SD, any increase, or no change (0 SD) in z-score for each domain (memory domain, executive function domain, and fine motor coordination domain). (NCT00525590)
Timeframe: Month 6
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Domains preserved=3 | Domains preserved=2 | Domains preserved=1 | Domains preserved=0 | |
| GLIADEL | 17 | 5 | 2 | 0 |
Preservation of NF was defined as a decrease of <=1 SD, any increase, or no change (0 SD) in z-score for each domain (memory domain, executive function domain, and fine motor coordination domain). (NCT00525590)
Timeframe: Month 9
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Domains preserved=3 | Domains preserved=2 | Domains preserved=1 | Domains preserved=0 | |
| GLIADEL | 14 | 6 | 0 | 0 |
(NCT00525590)
Timeframe: Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Local Recurrence | Distant Recurrence | Overall Recurrence | |
| GLIADEL | 28.0 | 48.0 | 62.0 |
Neurocognitive decline was defined as any decrease in NF scores less than (<) 0 SD from baseline. Here, in category titles EFD represents Executive Function Domain and FMCD represents Fine Motor Coordination Domain. (NCT00525590)
Timeframe: Months 2, 4, 6, 9 and 12
| Intervention | percentage of participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Month 2: Memory Domain, decline <0 to -1 SD | Month 2: Memory Domain, decline <-1 to -2 SD | Month 2: Memory Domain, decline <-2 to -3 SD | Month 2: Memory Domain, decline <-3 to -4 SD | Month 2: Memory Domain, decline <-4 to -5 SD | Month 2: Memory Domain, decline <-5 SD | Month 2: EFD, decline <0 to -1 SD | Month 2: EFD, decline <-1 to -2 SD | Month 2: EFD, decline <-2 to -3 SD | Month 2: EFD, decline <-3 to -4 SD | Month 2: EFD, decline <-4 to -5 SD | Month 2: EFD, decline <-5 SD | Month 2: FMCD, decline <0 to -1 SD | Month 2: FMCD, decline <-1 to -2 SD | Month 2: FMCD, decline <-2 to -3 SD | Month 2: FMCD, decline <-3 to -4 SD | Month 2: FMCD, decline <-4 to -5 SD | Month 2: FMCD, decline <-5 SD | Month 4: Memory Domain, decline <0 to -1 SD | Month 4: Memory Domain, decline <-1 to -2 SD | Month 4: Memory Domain, decline <-2 to -3 SD | Month 4: Memory Domain, decline <-3 to -4 SD | Month 4: Memory Domain, decline <-4 to -5 SD | Month 4: Memory Domain, decline <-5 SD | Month 4: EFD, decline <0 to -1 SD | Month 4: EFD, decline <-1 to -2 SD | Month 4: EFD, decline <-2 to -3 SD | Month 4: EFD, decline <-3 to -4 SD | Month 4: EFD, decline <-4 to -5 SD | Month 4: EFD, decline <-5 SD | Month 4: FMCD, decline <0 to -1 SD | Month 4: FMCD, decline <-1 to -2 SD | Month 4: FMCD, decline <-2 to -3 SD | Month 4: FMCD, decline <-3 to -4 SD | Month 4: FMCD, decline <-4 to -5 SD | Month 4: FMCD, decline <-5 SD | Month 6: Memory Domain, decline <0 to -1 SD | Month 6: Memory Domain, decline <-1 to -2 SD | Month 6: Memory Domain, decline <-2 to -3 SD | Month 6: Memory Domain, decline <-3 to -4 SD | Month 6: Memory Domain, decline <-4 to -5 SD | Month 6: Memory Domain, decline <-5 SD | Month 6: EFD, decline <0 to -1 SD | Month 6: EFD, decline <-1 to -2 SD | Month 6: EFD, decline <-2 to -3 SD | Month 6: EFD, decline <-3 to -4 SD | Month 6: EFD, decline <-4 to -5 SD | Month 6: EFD, decline <-5 SD | Month 6: FMCD, decline <0 to -1 SD | Month 6: FMCD, decline <-1 to -2 SD | Month 6: FMCD, decline <-2 to -3 SD | Month 6: FMCD, decline <-3 to -4 SD | Month 6: FMCD, decline <-4 to -5 SD | Month 6: FMCD, decline <-5 SD | Month 9: Memory Domain, decline <0 to -1 SD | Month 9: Memory Domain, decline <-1 to -2 SD | Month 9: Memory Domain, decline <-2 to -3 SD | Month 9: Memory Domain, decline <-3 to -4 SD | Month 9: Memory Domain, decline <-4 to -5 SD | Month 9: Memory Domain, decline <-5 SD | Month 9: EFD, decline <0 to -1 SD | Month 9: EFD, decline <-1 to -2 SD | Month 9: EFD, decline <-2 to -3 SD | Month 9: EFD, decline <-3 to -4 SD | Month 9: EFD, decline <-4 to -5 SD | Month 9: EFD, decline <-5 SD | Month 9: FMCD, decline <0 to -1 SD | Month 9: FMCD, decline <-1 to -2 SD | Month 9: FMCD, decline <-2 to -3 SD | Month 9: FMCD, decline <-3 to -4 SD | Month 9: FMCD, decline <-4 to -5 SD | Month 9: FMCD, decline <-5 SD | Month 12: Memory Domain, decline <0 to -1 SD | Month 12: Memory Domain, decline <-1 to -2 SD | Month 12: Memory Domain, decline <-2 to -3 SD | Month 12: Memory Domain, decline <-3 to -4 SD | Month 12: Memory Domain, decline <-4 to -5 SD | Month 12: Memory Domain, decline <-5 SD | Month 12: EFD, decline <0 to -1 SD | Month 12: EFD, decline <-1 to -2 SD | Month 12: EFD, decline <-2 to -3 SD | Month 12: EFD, decline <-3 to -4 SD | Month 12: EFD, decline <-4 to -5 SD | Month 12: EFD, decline <-5 SD | Month 12: FMCD, decline <0 to -1 SD | Month 12: FMCD, decline <-1 to -2 SD | Month 12: FMCD, decline <-2 to -3 SD | Month 12: FMCD, decline <-3 to -4 SD | Month 12: FMCD, decline <-4 to -5 SD | Month 12: FMCD, decline <-5 SD | |
| GLIADEL | 27.3 | 15.9 | 4.5 | 0 | 0 | 0 | 37.8 | 8.1 | 0 | 0 | 0 | 0 | 23.8 | 7.1 | 2.4 | 2.4 | 0 | 0 | 19.4 | 8.3 | 0 | 0 | 2.8 | 2.8 | 29.0 | 0 | 0 | 0 | 0 | 0 | 17.1 | 11.4 | 0 | 2.9 | 0 | 0 | 12.5 | 0 | 4.2 | 0 | 0 | 0 | 18.2 | 4.5 | 0 | 0 | 0 | 0 | 12.5 | 20.8 | 0 | 0 | 0 | 0 | 25.0 | 5.0 | 0 | 0 | 0 | 0 | 36.8 | 5.3 | 0 | 0 | 0 | 0 | 20.0 | 10.0 | 5.0 | 0 | 0 | 0 | 14.3 | 7.1 | 0 | 0 | 0 | 0 | 33.3 | 0 | 0 | 0 | 0 | 0 | 7.1 | 14.3 | 0 | 0 | 0 | 0 |
(NCT00525590)
Timeframe: Up to Month 12 (from baseline until evidence of neurological deterioration, had a local recurrence, withdrawn, died, lost to follow-up, or the study was closed)
| Intervention | months (Median) | ||
|---|---|---|---|
| Time to Local Recurrence | Time to Distant Recurrence | Time to Overall Recurrence | |
| GLIADEL | NA | 8.5 | 6.1 |
Reported as the number of Phase 1 participants by gemcitabine dose that experienced non-hematologic toxicity, ie, drug-related adverse events. (NCT00388349)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| 1250 mg/m2 Gemcitabine + HD Chemo + PBSC Rescue | 0 |
| 1500 mg/m2 Gemcitabine + HD Chemo + PBSC Rescue | 3 |
Reports the percentage of participants surviving 6 months after PBSC infusion (transplant). (NCT00388349)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Gemcitabine + High-dose Chemotherapy + PBSC Rescue | 87 |
Pulmonary toxicity as assessed by the number of participants that experience BCNU pneumonitis, ie, pneumonitis due to carmustine (BCNU). (NCT00388349)
Timeframe: 2 years
| Intervention | participants (Number) |
|---|---|
| Gemcitabine + High-dose Chemotherapy + PBSC Rescue | 26 |
Reports the percentage of participants that experienced relapse post-transplant. (NCT00388349)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Gemcitabine + High-dose Chemotherapy + PBSC Rescue | 29 |
"Reports the survival measures:~Freedom from progression (FFP)~Event-free survival (EFS)~Overall survival (OS)~EFS and OS were estimated by Kaplan-Meier method~Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions" (NCT00388349)
Timeframe: 2 years
| Intervention | percentage of patients (Number) | ||
|---|---|---|---|
| Freedom from Progression (FFP) | Event-Free Survival (EFS) | Overall Survival (OS) | |
| 1250 mg/m2 Gemcitabine + High-dose Chemotherapy + PBSC Rescue | 71 | 67 | 83 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
22 reviews available for carmustine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Biocompatible copolymer formulations to treat glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Polymers; Quality of | 2021 |
Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2017 |
[Treatment strategy of Hodgkin lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; B | 2014 |
Current medical treatment of glioblastoma.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, | 2015 |
Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Drug Implants; Gliom | 2015 |
Chemotherapeutic wafers for High Grade Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; H | 2008 |
Crossing borders: surgically mediated drug delivery techniques.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bacterial Toxins; Biological Availability; Brain Neop | 2008 |
[Chemotherapeutic wafers in treatment of malignant cerebral glioma. Assessment of a Cochrane review].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Evidence-Based Medici | 2010 |
Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
Chemotherapy wafers for high grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Decanoic | 2011 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic | 2003 |
Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; D | 2004 |
The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cr | 2005 |
Intracavitary chemotherapy (Gliadel) for recurrent esthesioneuroblastoma: case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Biocompatible Materials; Carmustine; Combined Modality The | 2006 |
Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Central Nervous System Neoplasms; Decanoic A | 2007 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dac | 2008 |
[Treatment strategy to obtain cure for recurrent advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carbo | 1994 |
Interstitial chemotherapy with sustained-release polymer systems for the treatment of malignant gliomas.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Brain Neoplasms; Carmustine; Chemotherapy, | 1994 |
High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults.
Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Chemotherapy | 2001 |
[Role of high-dose chemotherapy with hemopoietic stem-cell support in the treatment of adult patients with high-grade glioma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; C | 2001 |
Malignant astrocytic neoplasms: classification, pathologic anatomy, and response to treatment.
Topics: Aged; Astrocytoma; Brain; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; Male; Middle Ag | 1986 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1986 |
55 trials available for carmustine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etopos | 2022 |
Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn | 2013 |
Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn | 2013 |
Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn | 2013 |
Preservation of neurocognitive function and local control of 1 to 3 brain metastases treated with surgery and carmustine wafers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cogn | 2013 |
A multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2014 |
Safety evaluation of high-dose BCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas.
Topics: Absorbable Implants; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain | 2014 |
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2016 |
Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytara | 2016 |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Recep | 2009 |
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 2009 |
Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality The | 2010 |
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Catheters, Indwelling; | 2010 |
The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; | 2010 |
[Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astr | 2002 |
The surgical bed after BCNU polymer wafer placement for recurrent glioma: serial assessment on CT and MR imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Administration Rou | 2003 |
Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.
Topics: Absorbable Implants; Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain | 2003 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Pr | 2004 |
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; | 2004 |
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; C | 2004 |
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmusti | 2004 |
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Comb | 2005 |
Phase II trial of SarCNU in malignant glioma: unexpected pulmonary toxicity with a novel nitrosourea: a phase II trial of the national cancer institute of canada clinical trials group.
Topics: Academies and Institutes; Adult; Aged; Antineoplastic Agents; Astrocytoma; Canada; Carbon Monoxide; | 2005 |
SarCNU in recurrent or metastatic colorectal cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents; Canada; Carmustine; Colorectal Neoplasms; Dose-Response Relation | 2006 |
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combi | 2006 |
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carmustine; Combi | 2007 |
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Com | 2008 |
Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamid | 2008 |
Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; D | 1984 |
[Prospective randomized study in advanced stomach cancer. Comparison between combinations of 5-fluorouracil and carmustine without and with adriamycin].
Topics: Adult; Aged; Carmustine; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Leukocyte Cou | 1984 |
A prospective trial of 5-FU and BCNU in the treatment of advanced gastric cancer.
Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; | 1981 |
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera | 1981 |
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group.
Topics: Biodegradation, Environmental; Brain Neoplasms; Carmustine; Drug Implants; Female; Glioma; Humans; M | 1995 |
Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioma; Humans; Interfe | 1995 |
High-dose consolidation with local radiation and bone marrow rescue in patients with advanced neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Ca | 1994 |
High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Diseases; Carmu | 1996 |
High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplas | 1996 |
Contemporary chemotherapy issues for children with brainstem gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Brain Stem; Carboplatin; Carmustine; Dose-Response Relations | 1996 |
Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 1997 |
Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 1997 |
Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Female; Glioblastoma; H | 1998 |
Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Daca | 1998 |
Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1998 |
Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Carbop | 1998 |
A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 1999 |
Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etopos | 2000 |
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Central Nervous Syst | 2000 |
Pancreatic cancer treated with carmustine, fluorouracil, and spironolactone: a randomized study.
Topics: Adult; Carmustine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neopl | 1978 |
Nitrosoureas in multiple myeloma.
Topics: Carmustine; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Human | 1976 |
Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma | 1992 |
BAVC regimen in CR AML patients.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1991 |
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.
Topics: Brain Neoplasms; Carmustine; Decanoic Acids; Dicarboxylic Acids; Drug Combinations; Drug Implants; F | 1991 |
Alternating sequential intracarotid BCNU and cisplatin in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modalit | 1991 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1986 |
Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Tr | 1986 |
137 other studies available for carmustine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combi | 2021 |
Rituximab, Methotrexate, Carmustine, Etoposide, and Prednisone (RMBVP) for the treatment of relapsed/refractory primary central nervous system lymphoma: a retrospective single-center study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System; Central Ne | 2022 |
Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabi | 2022 |
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Central Nervous System; Centra | 2022 |
Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Humans; Hydrogels; Neoplasm Recurrence, Local | 2022 |
The nutritional impact of CD19-targeted CAR-T therapy versus BEAM chemotherapy for adult patients with lymphoma.
Topics: Adult; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Human | 2023 |
Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Central Nervous Syste | 2023 |
BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Ther | 2019 |
Hemophagocytic relapsed intramedullary plasmacytoma.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bo | 2020 |
Long-term follow-up after BCNU wafer implantation in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Coho | 2021 |
Implantation of Carmustine wafers after resection of malignant glioma with and without opening of the ventricular system.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioma; Humans; Neopl | 2021 |
Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neopl | 2017 |
Verapamil augments carmustine- and irradiation-induced senescence in glioma cells by reducing intracellular reactive oxygen species and calcium ion levels.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium; Calcium Channels, L-Type; Carmustine; Cell | 2017 |
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; | 2018 |
Tumor microenvironment after biodegradable BCNU wafer implantation: special consideration of immune system.
Topics: Absorbable Implants; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain | 2018 |
Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; B | 2018 |
Importance and accuracy of intraoperative frozen section diagnosis of the resection margin for effective carmustine wafer implantation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 2018 |
A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
Topics: AC133 Antigen; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Brain Neopl | 2019 |
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progres | 2019 |
Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carmustin | 2015 |
Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-F | 2013 |
Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Etoposi | 2014 |
Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Comb | 2014 |
Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Disease-Fr | 2014 |
Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2014 |
Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Child; Cyclophosphamide; Etoposide; Fema | 2015 |
[A Case of Symptomatic Cyst Formation after BCNU Wafer Implantation for Glioblastoma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cysts; Fe | 2015 |
Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carmustine; Combined Modality Therapy; Disease-Free Surv | 2016 |
Patterns of Recurrence After Resection of Malignant Gliomas With BCNU Wafer Implants: Retrospective Review in a Single Institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2016 |
Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Transpla | 2008 |
Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Topics: Adult; Age Factors; Aged; Biomarkers, Tumor; Brain Neoplasms; Carmustine; DNA Methylation; Drug Impl | 2009 |
Incorporating BCNU wafers into malignant glioma treatment: European case studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2010 |
Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Cell Adhesion; Cell C | 2010 |
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado; | 2011 |
Treatment of recurrent glioblastoma with intra-arterial BCNU [1, 3-bis (2-chloroethyl)-1-nitrosourea].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; | 2010 |
Occlusion of surgical opening of the ventricular system with fibrinogen-coated collagen fleece: a case collection study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Cerebral V | 2011 |
Gliadel wafers acting as a lattice for bacterial growth: a case illustration.
Topics: Anti-Bacterial Agents; Biocompatible Materials; Brain Neoplasms; Carmustine; Central Nervous System | 2011 |
Comment on Bock et al. Occlusion of surgical opening of the ventricular system with fibrinogen-coated collagen fleece: a case collection study. Acta Neurochir (2011) 153:533-539.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Cerebral Ventricle Neop | 2012 |
Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dru | 2012 |
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastomas.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Male; Neoplasm Recurrence, Local | 2012 |
Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Daca | 2012 |
Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2012 |
Establishing the efficacy of Gliadel wafers: progress towards a Phase III trial.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Male; Neoplasm Recurrence, Local | 2013 |
Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; | 2013 |
Growth pattern of tumor recurrence following bis-chloroethylnitrosourea (BCNU) wafer implantation in malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Kaplan-Meier | 2013 |
Prolonged survival associated with the use of intraoperative carmustine (Gliadel) in a paediatric patient with recurrent grade III astrocytoma.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Carmustine; Combi | 2013 |
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2003 |
Intracavitary chemotherapy for glioblastoma: present status and future directions.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therap | 2003 |
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2003 |
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2003 |
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2003 |
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2003 |
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2003 |
Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma.
Topics: Absorbable Implants; Adolescent; Adult; Age Distribution; Aged; Antineoplastic Agents, Alkylating; B | 2004 |
Invasive phenotype observed in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant sublines of 9L rat glioma cells: a tumor model mimicking a recurrent malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Culture Techniques; Ce | 2004 |
Lack of survival benefit after stereotactic radiosurgery boost for glioblastoma multiforme: randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients
Topics: Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; Female; Glioblastoma; Huma | 2005 |
[Management of malignant gliomas diagnosed during pregnancy].
Topics: Abortion, Therapeutic; Adrenal Cortex Hormones; Adult; Algorithms; Anesthesia, General; Antineoplast | 2006 |
Patient with resected anaplastic astrocytoma and an image suggestive of relapse.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Edema; Brain Neoplasms; Carmustine; Com | 2006 |
Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytara | 2007 |
Fatal outcome related to carmustine implants in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemothera | 2007 |
Spontaneous pregnancy and normal delivery after repeated autologous bone marrow transplantation and GnRH agonist treatment.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 2007 |
[Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2007 |
High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarab | 2008 |
Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain; Brain Neoplasms; Carmust | 2008 |
High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 2008 |
High dose BCNU with autologous bone marrow rescue in the treatment of recurrent malignant gliomas.
Topics: Adult; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dose-Res | 1983 |
Sequential half-body irradiation (SHBI) and combination chemotherapy as salvage treatment for failed Ewing's sarcoma--a pilot study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Child; Fluor | 1984 |
Long term survival among patients with malignant brain tumors.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Female; Glioblastoma; Humans; M | 1982 |
Effect of age and reoperation on survival in the combined modality treatment of malignant astrocytoma.
Topics: Adolescent; Adult; Age Factors; Aged; Brain Neoplasms; Carmustine; Dimethyl Sulfoxide; Doxorubicin; | 1982 |
Spinal leptomeningeal invasion from intracranial glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Cauda Equina; Cerebrospinal Fluid; Child, Preschool; Cobalt Radioisotop | 1983 |
Treatment of recurrent brain tumors with intra-arterial cis-platinum and BCNU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Ar | 1984 |
Therapeutic benefits of combination chemotherapy with vincristine, BCNU, and procarbazine on recurrent cystic craniopharyngioma. A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Craniopharyngiom | 1984 |
Chemotherapy-induced fatal pulmonary fibrosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child, Preschool; Epend | 1984 |
Intra-arterial BCNU in the treatment of metastatic brain tumors.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Humans; Infusions, Intr | 1983 |
[Fatal pulmonary fibrosis induced by cytotoxic therapy].
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Child, Preschool; Ependymoma; Female; Hum | 1984 |
[Chemotherapy of stomach cancer].
Topics: Adenocarcinoma; Antineoplastic Agents; Carmustine; Cisplatin; Doxorubicin; Drug Administration Sched | 1982 |
Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Dianhydrogalactitol; Drug Therapy, Combinatio | 1982 |
Medulloblastoma in childhood. Multidisciplinary treatment.
Topics: Adolescent; Carmustine; Cerebellar Neoplasms; Cerebellum; Child; Child, Preschool; Female; Humans; I | 1982 |
Maintenance of MOPC 104E myeloma in plateau phase.
Topics: Animals; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dose-Response Relationship, | 1980 |
Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up.
Topics: Biopsy; Carmustine; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Mechlorethamine; Middle | 1995 |
Low-dose chemotherapy delays relapse of a dominated and resistant sub-population in a heterogeneous human SCLC xenograft in nude mice.
Topics: Animals; Carcinoma, Small Cell; Carmustine; DNA, Neoplasm; Drug Resistance; Humans; Lung Neoplasms; | 1994 |
High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1993 |
Intralesional implant for treatment of primary oral malignant melanoma in dogs.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Delayed-Action Prepa | 1994 |
A dominated and resistant subpopulation causes regrowth after response to 1,3-bis(2-chloroethyl)-1-nitrosourea treatment of a heterogeneous small cell lung cancer xenograft in nude mice.
Topics: Animals; Biopsy, Needle; Carcinoma, Small Cell; Carmustine; Cell Division; DNA, Neoplasm; Drug Resis | 1994 |
Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 1997 |
High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; | 1998 |
Beyond the barrier: devices inside the brain.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioma; Humans; Neopl | 1995 |
Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cohort Studi | 1999 |
Serial CT and MR imaging of carmustine wafers.
Topics: Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Diseases; Carmustine; Drug Deliver | 2000 |
Hematologic toxic reaction to radiation therapy adjuvant to autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin disease.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplas | 2000 |
Tumor bed cyst formation after BCNU wafer implantation: report of two cases.
Topics: Antineoplastic Agents, Alkylating; Brain Diseases; Brain Neoplasms; Carmustine; Chemotherapy, Adjuva | 2000 |
Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biologica | 2000 |
Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cataract; Co | 2000 |
Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy | 1999 |
Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2000 |
Shunt-related abdominal metastases in an infant with medulloblastoma: long-term remission by systemic chemotherapy and surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cerebellar Neoplasms; Combi | 2001 |
Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine | 2001 |
Accelerated hazards regression model and its adequacy for censored survival data.
Topics: Antineoplastic Agents, Alkylating; Biometry; Brain Neoplasms; Carmustine; Glioma; Humans; Neoplasm R | 2001 |
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cy | 2001 |
A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillo | 2001 |
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclop | 2002 |
Chemotherapy in recurrent noncystic low-grade astrocytomas of the cerebrum in children.
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Child, Preschool; Dexamethas | 1978 |
Surgical therapy of primary malignant brain tumors.
Topics: Adrenal Cortex Hormones; Adult; Aged; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Mid | 1978 |
Chemotherapy for known residual disease after resection of gastric and colorectal cancer.
Topics: Carcinoembryonic Antigen; Carmustine; Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; H | 1978 |
Nitrosourea chemotherapy for primary malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glioma; Humans; Lomustine; Neo | 1976 |
A murine model for central nervous system leukemia and its possible relevance to human leukemia.
Topics: Amphotericin B; Animals; Brain; Carmustine; Central Nervous System Diseases; Disease Models, Animal; | 1975 |
Long-term survival of patients treated with BCNU for brain tumors.
Topics: Adolescent; Adult; Astrocytoma; Bone Marrow; Brain; Brain Neoplasms; Carmustine; Dose-Response Relat | 1975 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Selective intra-arterial chemotherapy with BCNU in recurrent malignant gliomas.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; Infusions, Intra-Arte | 1992 |
High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1992 |
Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cis | 1992 |
Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem | 1992 |
Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow | 1991 |
Treatment of refractory and relapsed Hodgkin's disease: intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transpla | 1990 |
Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cis-platinum (CDDP) and i.v. BCNU. A phase II trial.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplas | 1990 |
Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Carmustine; Drug Administration Schedule; | 1990 |
Intra-arterial BCNU in the treatment of recurrent medulloblastoma.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Humans; Injections, Intra-Arterial; Male; Medulloblastom | 1990 |
[Intra-arterial chemotherapy of local recurrences of gastrointestinal tumors].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colorectal Neopla | 1989 |
Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha-difluoromethylornithine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1989 |
Tumour recurrence vs radionecrosis: an indication for multitrajectory serial stereotactic biopsies.
Topics: Astrocytoma; Biopsy, Needle; Brain; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1989 |
Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1989 |
Intravenous BCNU and AZQ in patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; | 1989 |
Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Carotid Arteries | 1985 |
Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Aziridines; Azirines; Benzoquinones; Bone Marrow; B | 1986 |
Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Aziridines; Be | 1987 |
Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Combined Modality Therapy; Follow-Up Stu | 1987 |
Medulloblastoma at the joint center for radiation therapy between 1968 and 1984. The influence of radiation dose on the patterns of failure and survival.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cerebellar Neoplasms; | 1988 |
Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies.
Topics: Adolescent; Adult; Aged; Brain; Brain Neoplasms; Carmustine; Child; Child, Preschool; Deoxyglucose; | 1988 |
M-2 protocol for melphalan-resistant and relapsing multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Marrow; Carmustine | 1988 |
Patterns of recurrence in glioma patients after interstitial irradiation and chemotherapy: report of three cases.
Topics: Adult; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioma; Humans | 1988 |
Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carmustine; Com | 1987 |
Intracarotid chemotherapy with 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) in 5% dextrose in water in the treatment of malignant glioma.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Combined Modality Therapy; | 1987 |
Treatment of recurrent esthesioneuroblastoma with combined intra-arterial chemotherapy. A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Female; Humans; Infusio | 1987 |
Mumps virus and BCG vaccine in metastatic melanoma.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; BCG Vaccine; Carmustine; Female; Humans; Imm | 1973 |
Hypertrophic scar after cryotherapy and topical tretinoin.
Topics: Administration, Topical; Carcinoma, Basal Cell; Carmustine; Cicatrix; Connective Tissue; Cryosurgery | 1973 |
An analysis of Ewing's tumor in children at Roswell Park Memorial Institute.
Topics: Adolescent; Autopsy; Carmustine; Child; Child, Preschool; Cyclophosphamide; Female; Follow-Up Studie | 1972 |